Boston Scientific (BSX) 10-Q 3 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Jul. 31, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	BOSTON SCIENTIFIC CORPORATION
Entity Central Index Key	885,725
Document Type	10-Q
Document Period End Date	Jun. 30, 2017
Amendment Flag	false
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		1,372,127,044

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net sales	$ 2,257	$ 2,126	$ 4,418	$ 4,090
Cost of products sold	632	639	1,282	1,211
Gross profit	1,625	1,487	3,136	2,879
Operating expenses:
Selling, general and administrative expenses	815	779	1,609	1,497
Research and development expenses	244	222	480	431
Royalty expense	17	20	34	39
Amortization expense	142	135	285	271
Restructuring charges (credits)	1	14	5	17
Contingent consideration expense (benefit)	(24)	33	(74)	37
Litigation-related charges (credits)	205	618	208	628
Operating expenses	1,400	1,821	2,547	2,920
Operating income (loss)	225	(334)	589	(41)
Other income (expense):
Interest expense	(58)	(59)	(115)	(118)
Other, net	(76)	(4)	(78)	(10)
Income (loss) before income taxes	91	(397)	396	(169)
Income tax expense (benefit)	(55)	(190)	(40)	(164)
Net income (loss)	$ 146	$ (207)	$ 436	$ (5)
Net income (loss) per common share — basic	$ 0.11	$ (0.15)	$ 0.32	$ 0
Net income (loss) per common share — assuming dilution	$ 0.11	$ (0.15)	$ 0.31	$ 0
Weighted-average shares outstanding
Basic	1,369.8	1,357.4	1,367.6	1,353.9
Assuming dilution	1,391.1	1,357.4	1,390.6	1,353.9

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net income (loss)	$ 146	$ (207)	$ 436	$ (5)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment	13	(21)	21	(5)
Net change in unrealized gains and losses on derivative financial instruments	(21)	(84)	(76)	(153)
Net change in available-for-sale securities	2	0	2	0
Net change in unrealized costs associated with certain retirement plans	(1)	0	(1)	0
Total other comprehensive income (loss)	(7)	(105)	(54)	(158)
Total comprehensive income (loss)	$ 139	$ (312)	$ 382	$ (163)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 195	$ 196
Trade accounts receivable, net	1,444	1,472
Inventories	1,023	955
Deferred and prepaid income taxes	75	75
Other current assets	485	541
Total current assets	3,222	3,239
Property, plant and equipment, net	1,651	1,630
Goodwill	6,871	6,678
Other intangible assets, net	5,921	5,883
Other long-term assets	717	666
TOTAL ASSETS	18,382	18,096
Current liabilities:
Current debt obligations	1,018	64
Accounts payable	376	447
Accrued expenses	2,238	2,312
Other current liabilities	668	764
Total current liabilities	4,300	3,587
Long-term debt	4,817	5,420
Deferred income taxes	58	18
Other long-term liabilities	1,972	2,338
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.01 par value - authorized 50,000,000 shares, none issued and outstanding
Common stock, $0.01 par value - authorized 2,000,000,000 shares - issued 1,618,030,825 shares as of June 30, 2017 and 1,609,670,817 shares as of December 31, 2016	16	16
Treasury stock, at cost - 247,566,270 shares as of June 30, 2017 and December 31, 2016	(1,717)	(1,717)
Additional paid-in capital	17,057	17,014
Accumulated deficit	(8,068)	(8,581)
Accumulated other comprehensive income (loss), net of tax	(53)	1
Total stockholders’ equity	7,235	6,733
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 18,382	$ 18,096

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2017	Dec. 31, 2016
Condensed Consolidated Balance Sheet (Parenthetical) [Abstract]
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000
Common Stock, Shares, Issued	1,618,030,825	1,609,670,817
Common Stock, Shares, Outstanding	1,370,464,555	1,362,104,547
Preferred Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Preferred Stock, Shares Authorized	50,000,000	50,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Treasury Stock, Shares	247,566,270	247,566,270

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash provided by (used for) operating activities
Cash provided by (used for) operating activities	$ 299	$ 537
Investing activities:
Purchases of property, plant and equipment	(180)	(138)
Proceeds on disposals of property, plant and equipment	0	29
Payments for acquisitions of businesses, net of cash acquired	(392)	0
Net payments for investments, acquisitions of certain technologies and issuances of notes receivable	(47)	(41)
Cash provided by (used for) investing activities	(619)	(150)
Financing activities:
Payments on long-term borrowings	(600)	(250)
Net increase (decrease) in commercial paper	1,013	0
Payment of contingent consideration amounts previously established in purchase accounting	(18)	(35)
Proceeds from borrowings on credit facilities	2,156	40
Payments on borrowings from credit facilities	(2,216)	(40)
Cash used to net share settle employee equity awards	(62)	(56)
Proceeds from issuances of shares of common stock	44	73
Cash provided by (used for) financing activities	317	(268)
Effect of foreign exchange rates on cash	2	0
Net increase (decrease) in cash and cash equivalents	(1)	119
Cash and cash equivalents at beginning of period	196	319
Cash and cash equivalents at end of period	195	438
Supplemental Information
Stock-based compensation expense	$ 62	$ 58

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2017
Basis of Presentation [Abstract]
BASIS OF PRESENTATION	NOTE A – BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements of Boston Scientific Corporation have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for fair presentation have been included. Operating results for the three and six months ended June 30, 2017 are not necessarily indicative of the results that may be expected for the year ending December 31, 2017 . For further information, refer to the consolidated financial statements and footnotes thereto included in Item 8 of our most recent Annual Report on Form 10-K. Subsequent Events We evaluate events occurring after the date of our most recent accompanying unaudited condensed consolidated balance sheets for potential recognition or disclosure in our financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying unaudited condensed consolidated financial statements (recognized subsequent events) for the three and six months ended June 30, 2017 . Those items requiring disclosure (unrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note E – Borrowings and Credit Arrangements and Note I – Commitments and Contingencies for more information.

Acquisitions and Strategic Inve

Acquisitions and Strategic Investments	6 Months Ended
	Jun. 30, 2017
Business Combinations [Abstract]
ACQUISITIONS AND STRATEGIC INVESTMENTS	NOTE B – ACQUISITIONS AND STRATEGIC INVESTMENTS 2017 Acquisitions Symetis SA On May 16, 2017 we completed the acquisition of Symetis SA (Symetis) for approximately $430 million in cash. Symetis is a privately-held Swiss structural heart company focused on minimally-invasive transcatheter aortic valve implantation (TAVI) devices. Upon completion of the acquisition, we began selling the ACURATE TA™, ACURATE neo™ ACURATE TF™ Valve Systems in Europe and in other geographies outside of the United States. We are in the process of integrating Symetis into our Interventional Cardiology business and expect the integration to be substantially complete by the end of 2018. Purchase Price Allocation We accounted for the acquisition of Symetis as a business combination and, in accordance with FASB ASC Topic 805 , Business Combinations , we recorded the assets acquired and liabilities assumed at their respective fair values as of the acquisition date. The components of the aggregate preliminary purchase price are as follows (in millions): Net cash paid for acquisition $ 392 The following summarizes the preliminary purchase price allocation for the Symetis acquisition as of June 30, 2017 (in millions): Goodwill $ 185 Amortizable intangible assets 278 Other assets acquired 25 Liabilities assumed (96 ) $ 392 We allocated a portion of the purchase price to specific intangible asset categories as follows: Amount Assigned (in millions) Amortization Period (in years) Range of Risk- Adjusted Discount Rates used in Purchase Price Allocation Amortizable intangible assets: Technology-related $ 268 13 23.5% Other intangible assets 10 2-13 23.5% $ 278 2016 Acquisitions We did not close any significant acquisitions during the first half of 2016. Contingent Consideration Certain of our acquisitions involve contingent consideration arrangements. Payment of additional consideration is generally contingent on the acquired company reaching certain performance milestones, including attaining specified revenue levels, achieving product development targets and/or obtaining regulatory approvals for products in development at the date of the acquisition. In accordance with U.S. GAAP, we recognize a liability equal to the fair value of the contingent payments we expect to make as of the acquisition date. We re-measure this liability each reporting period and record changes in the fair value through a separate line item within our condensed consolidated statements of operations. We recorded a net benefit related to the changes in fair value of our contingent consideration liabilities of $24 million during the second quarter of 2017 and $74 million during the first half of 2017 . We recorded net expenses related to the changes in fair value of our contingent consideration liabilities of $33 million during the second quarter of 2016 and $37 million during the first half of 2016 . We paid contingent consideration of $28 million during the first half of 2017 and $77 million during the first half of 2016 . Changes in the fair value of our contingent consideration liabilities were as follows (in millions): Balance as of December 31, 2016 $ 204 Fair value adjustments (74 ) Contingent payments related to prior period acquisitions (28 ) Balance as of June 30, 2017 $ 102 As of June 30, 2017 , the maximum amount of future contingent consideration (undiscounted) that we could be required to pay was approximately $1.278 billion . Contingent consideration liabilities are remeasured to fair value each reporting period using projected revenues, discount rates, probabilities of payment and projected payment dates. The recurring Level 3 fair value measurements of our contingent consideration liabilities include the following significant unobservable inputs: Contingent Consideration Liabilities Fair Value as of June 30, 2017 Valuation Technique Unobservable Input Range R&D and Commercialization-based Milestones $44 million Discounted Cash Flow Discount Rate 2% - 3% Projected Year of Payment 2017 - 2021 Revenue-based Payments $58 million Discounted Cash Flow Discount Rate 11% - 15% Projected Year of Payment 2017 - 2026 Increases or decreases in the fair value of our contingent consideration liabilities can result from changes in discount periods and rates, as well as changes in the timing and amount of revenue estimates or in the timing or likelihood of achieving R&D, commercialization-based, and revenue-based milestones. Projected contingent payment amounts related to some of our R&D, commercialization-based, and revenue-based milestones are discounted back to the current period using a discounted cash flow model. Projected revenues are based on our most recent internal operational budgets and long-range strategic plans. Increases in projected revenues and probabilities of payment may result in higher fair value measurements. Increases in discount rates and the time to payment may result in lower fair value measurements. Increases or decreases in any of those inputs together, or in isolation, may result in a significantly lower or higher fair value measurement. Strategic Investments We did not close any material strategic investments during the first half of 2017 or 2016 . We account for certain of our strategic investments as equity method investments, in accordance with FASB ASC Topic 323, Investments - Equity Method and Joint Ventures . The aggregate carrying amount of our strategic investments as of June 30, 2017 and December 31, 2016 were comprised of the following categories: As of (in millions) June 30, 2017 December 31, 2016 Equity method investments $ 208 $ 265 Cost method investments 42 20 Available-for-sale securities 30 20 Notes receivable 44 42 $ 324 $ 347 These investments are classified as other long-term assets within our accompanying unaudited condensed consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. During the second quarter of 2017 , we recorded a charge of $53 million for an other-than-temporary impairment loss equal to the difference between the carrying value of one of our investments and its fair value. The charge was recorded within the Other, net caption of our unaudited condensed consolidated statement of operations.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	NOTE C – GOODWILL AND OTHER INTANGIBLE ASSETS The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill as of June 30, 2017 and December 31, 2016 are as follows: As of June 30, 2017 December 31, 2016 Gross Carrying Accumulated Gross Accumulated (in millions) Amount Write-offs Amount Write-offs Amortizable intangible assets Technology-related $ 9,390 $ (4,675 ) $ 9,123 $ (4,468 ) Patents 511 (370 ) 529 (374 ) Other intangible assets 1,632 (779 ) 1,583 (722 ) $ 11,533 $ (5,824 ) $ 11,235 $ (5,564 ) Unamortizable intangible assets Goodwill $ 16,771 $ (9,900 ) $ 16,578 $ (9,900 ) In-process research and development (IPR&D) 92 — 92 — Technology-related 120 — 120 — $ 16,983 $ (9,900 ) $ 16,790 $ (9,900 ) Our technology-related intangible assets that are not subject to amortization represent technical processes, intellectual property and/or institutional understanding acquired through business combinations that are fundamental to the on-going operations of our business and have no limit to their useful life. Our technology-related intangible assets that are not subject to amortization are comprised primarily of certain acquired balloon and other technology, which is foundational to our continuing operations within the Cardiovascular market and other markets within interventional medicine. We assess our indefinite-lived intangible assets at least annually for impairment and reassess their classification as indefinite-lived assets. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other . The following represents our goodwill balance by global reportable segment: (in millions) Cardiovascular Rhythm Management MedSurg Total Balance as of December 31, 2016 $ 3,513 $ 290 $ 2,875 $ 6,678 Impact of foreign currency fluctuations and other changes in carrying amount 4 1 3 8 Goodwill acquired 185 — — 185 Balance as of June 30, 2017 $ 3,702 $ 291 $ 2,878 $ 6,871 Goodwill Impairment Testing In the second quarter of 2017 , we performed our annual goodwill impairment test for all of our reporting units and concluded the fair value of each reporting unit exceeded its carrying value. Based on the criteria prescribed in FASB ASC Topic 350 , we assess goodwill for impairment at the reporting unit level, which is defined as an operating segment or one level below an operating segment, referred to as a component. For our 2017 and 2016 annual impairment assessment, we identified seven reporting units: Interventional Cardiology, Peripheral Interventions, Cardiac Rhythm Management, Electrophysiology, Endoscopy, Urology and Pelvic Health and Neuromodulation. We aggregated the Cardiac Rhythm Management and Electrophysiology reporting units, components of the Rhythm Management operating segment, based on the criteria prescribed in FASB ASC Topic 350 . These reporting units were aggregated due to a reorganization that commenced in 2015 that resulted in integrated leadership, shared resources and consolidation of certain sites in 2016. In performing the goodwill impairment assessment, we utilized both the optional qualitative assessment and the quantitative approach prescribed under FASB ASC Topic 350 . The qualitative assessment was used for testing certain reporting units where fair value has historically exceeded carrying value by greater than 100 percent. All other reporting units were tested using the quantitative approach. After assessing the totality of events, if it is determined that it is not more likely than not that the fair value of the reporting unit is less than its carrying value, the quantitative approach of the goodwill impairment test is unnecessary. In 2017, for all reporting units tested using the optional qualitative assessment, we concluded that it was not necessary to perform the quantitative impairment test. For all reporting units tested using the quantitative approach, we concluded that the fair value of each reporting unit exceeded its carrying value. Refer to Critical Accounting Policies and Estimates within Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in Item 2 of this Quarterly Report on Form 10-Q for further discussion of our annual goodwill impairment testing. The following is a rollforward of accumulated goodwill write-offs by global reportable segment: (in millions) Cardiovascular Rhythm Management MedSurg Total Accumulated write-offs as of December 31, 2016 $ (1,479 ) $ (6,960 ) $ (1,461 ) $ (9,900 ) Goodwill written off — — — — Accumulated write-offs as of June 30, 2017 $ (1,479 ) $ (6,960 ) $ (1,461 ) $ (9,900 )

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE D – FAIR VALUE MEASUREMENTS Derivative Instruments and Hedging Activities We address market risk from changes in foreign currency exchange rates and interest rates through a risk management program that includes the use of derivative financial instruments and we operate the program pursuant to documented corporate risk management policies. Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives generally offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to FASB ASC Topic 815 , Derivatives and Hedging . Currency Hedging We are exposed to currency risk consisting primarily of foreign currency denominated monetary assets and liabilities, forecasted foreign currency denominated intercompany transactions and third-party transactions, and net investments in certain subsidiaries. We manage our exposure to changes in foreign currency exchange rates on a consolidated basis to take advantage of offsetting transactions. We use derivative instruments and non-derivative transactions to reduce the risk that our earnings and cash flows associated with these foreign currency denominated balances and transactions will be adversely affected by foreign currency exchange rate changes. Currently or Previously Designated Foreign Currency Hedges All of our designated currency hedge contracts outstanding as of June 30, 2017 and December 31, 2016 were cash flow hedges under FASB ASC Topic 815 intended to protect the U.S. dollar value of our forecasted foreign currency denominated transactions. We record the effective portion of any change in the fair value of foreign currency cash flow hedges in other comprehensive income (OCI) until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the foreign currency cash flow hedge to earnings. In the event the hedged forecasted transaction does not occur, or it becomes no longer probable that it will occur, we reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had currency derivative instruments designated as cash flow hedges outstanding in the contract amount of $2.915 billion as of June 30, 2017 and $2.271 billion as of December 31, 2016 . We recognized net gains of $27 million in earnings on our cash flow hedges during the second quarter of 2017 and $55 million during the first half of 2017 , as compared to net gains of $32 million during the second quarter of 2016 and $80 million during the first half of 2016 . All currency cash flow hedges outstanding as of June 30, 2017 mature within 60 months. As of June 30, 2017 , $25 million of net gains , net of tax, were recorded in accumulated other comprehensive income (AOCI) to recognize the effective portion of the fair value of any currency derivative instruments that are, or previously were, designated as foreign currency cash flow hedges, as compared to net gains , net of tax, of $102 million as of December 31, 2016 . As of June 30, 2017 , an immaterial amount may be reclassified to earnings within the next twelve months. The success of our hedging program depends, in part, on forecasts of transaction activity in various currencies (primarily British pound sterling, Euro and Japanese yen). We may experience unanticipated currency exchange gains or losses to the extent that there are differences between forecasted and actual activity during periods of currency volatility. In addition, changes in foreign currency exchange rates related to any unhedged transactions may impact our earnings and cash flows. Non-designated Foreign Currency Contracts We use currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These currency forward contracts are not designated as cash flow, fair value or net investment hedges under FASB ASC Topic 815 . The currency forward contracts are marked-to-market with changes in fair value recorded to earnings and are entered into for periods consistent with currency transaction exposures, generally less than one year. We had currency derivative instruments not designated as hedges under FASB ASC Topic 815 outstanding in the contract amount of $2.197 billion as of June 30, 2017 and $1.830 billion as of December 31, 2016 . Interest Rate Hedging Our interest rate risk relates primarily to U.S. dollar borrowings, partially offset by U.S. dollar cash investments. We have historically used interest rate derivative instruments to manage our earnings and cash flow exposure to changes in interest rates by converting fixed-rate debt into floating-rate debt or floating-rate debt into fixed-rate debt. We had no interest rate derivative instruments outstanding as of June 30, 2017 and December 31, 2016 . We designate these derivative instruments either as fair value or cash flow hedges under FASB ASC Topic 815 . We record changes in the value of fair value hedges in interest expense, which is generally offset by changes in the fair value of the hedged debt obligation. Interest payments made or received related to our interest rate derivative instruments are included in interest expense. We record the effective portion of any change in the fair value of derivative instruments designated as cash flow hedges as unrealized gains or losses in OCI, net of tax, until the hedged cash flow occurs, at which point the effective portion of any gain or loss is reclassified to earnings. We record the ineffective portion of our cash flow hedges in interest expense. In the event the hedged cash flow does not occur, or it becomes no longer probable that it will occur, we reclassify the amount of any gain or loss on the related cash flow hedge to interest expense at that time. We are amortizing the gains and losses on previously terminated interest rate derivative instruments, including fixed-to-floating interest rate contracts designated as fair value hedges and forward starting interest rate derivative contracts designated as cash flow hedges into earnings as a component of interest expense over the remaining term of the hedged debt, in accordance with FASB ASC Topic 815 . The carrying amount of certain of our senior notes included unamortized gains of $45 million as of June 30, 2017 and $51 million as of December 31, 2016 . We had no unamortized losses as of June 30, 2017 compared to an immaterial amount as of December 31, 2016 . In addition, we had pre-tax net gains within AOCI related to terminated forward starting interest rate derivative contracts of $8 million as of June 30, 2017 and $9 million as of December 31, 2016 . The net gains that we recognized as a reduction of interest expense in earnings related to previously terminated interest rate derivatives were $3 million during the second quarter of 2017 and $6 million during the first half of 2017 , as compared to $3 million during the second quarter of 2016 and $6 million during the first half of 2016 . As of June 30, 2017 , $14 million of net gains may be reclassified to earnings within the next twelve months from amortization of our previously terminated interest rate derivative contracts. Counterparty Credit Risk We do not have significant concentrations of credit risk arising from our derivative financial instruments, whether from an individual counterparty or a related group of counterparties. We manage our concentration of counterparty credit risk on our derivative instruments by limiting acceptable counterparties to a diversified group of major financial institutions with investment grade credit ratings, limiting the amount of credit exposure to each counterparty and by actively monitoring their credit ratings and outstanding fair values on an on-going basis. Furthermore, none of our derivative transactions are subject to collateral or other security arrangements and none contain provisions that are dependent on our credit ratings from any credit rating agency. We also employ master netting arrangements that reduce our counterparty payment settlement risk on any given maturity date to the net amount of any receipts or payments due between us and the counterparty financial institution. Thus, the maximum loss due to counterparty credit risk is limited to the unrealized gains in such contracts net of any unrealized losses should any of these counterparties fail to perform as contracted. Although these protections do not eliminate concentrations of credit risk, as a result of the above considerations, we do not consider the risk of counterparty default to be significant. Fair Value of Derivative Instruments The following presents the effect of our derivative instruments designated as cash flow hedges under FASB ASC Topic 815 on our accompanying unaudited condensed consolidated statements of operations during the second quarter and the first half of 2017 and 2016 : (in millions) Amount of Pre-tax Gain (Loss) Recognized in OCI (Effective Portion) Amount of Pre-tax Gain (Loss) Reclassified from AOCI into Earnings (Effective Portion) Location in Statement of Operations Three Months Ended June 30, 2017 Currency hedge contracts $ (6 ) $ 27 Cost of products sold $ (6 ) $ 27 Three Months Ended June 30, 2016 Currency hedge contracts $ (99 ) $ 32 Cost of products sold $ (99 ) $ 32 Six Months Ended June 30, 2017 Currency hedge contracts $ (64 ) $ 55 Cost of products sold Interest rate derivative contracts — 1 Interest Expense $ (64 ) $ 56 Six Months Ended June 30, 2016 Currency hedge contracts $ (158 ) $ 80 Cost of products sold $ (158 ) $ 80 The amount of gain (loss) recognized in earnings related to the ineffective portion of hedging relationships was immaterial in all periods presented. Net gains and losses on currency hedge contracts not designated as hedging instruments were offset by net losses and gains from foreign currency transaction exposures, as shown in the following table: (in millions) Location in Statement of Operations Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Net gain (loss) on currency hedge contracts Other, net $ 5 $ (28 ) $ (12 ) $ (67 ) Net gain (loss) on foreign currency transaction exposures Other, net (13 ) 29 4 63 Net foreign currency gain (loss) Other, net $ (8 ) $ 1 $ (8 ) $ (4 ) FASB ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures , by considering the estimated amount we would receive or pay to transfer these instruments at the reporting date and by taking into account current interest rates, foreign currency exchange rates, the creditworthiness of the counterparty for the assets and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability, and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of June 30, 2017 , we have classified all of our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by FASB ASC Topic 820 , as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments. The following are the balances of our derivative assets and liabilities as of June 30, 2017 and December 31, 2016 : As of June 30, December 31, (in millions) Location in Balance Sheet (1) 2017 2016 Derivative Assets: Currently or Previously Designated Hedging Instruments Currency hedge contracts Other current assets $ 20 $ 98 Currency hedge contracts Other long-term assets 52 65 72 163 Non-Designated Hedging Instruments Currency hedge contracts Other current assets 24 36 Total Derivative Assets $ 96 $ 199 Derivative Liabilities: Currently or Previously Designated Hedging Instruments Currency hedge contracts Other current liabilities $ 25 $ 3 Currency hedge contracts Other long-term liabilities 11 4 36 7 Non-Designated Hedging Instruments Currency hedge contracts Other current liabilities 34 19 Total Derivative Liabilities $ 70 $ 26 (1) We classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less. Other Fair Value Measurements Recurring Fair Value Measurements On a recurring basis, we measure certain financial assets and financial liabilities at fair value based upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value. FASB ASC Topic 820 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows: • Level 1 – Inputs to the valuation methodology are quoted market prices for identical assets or liabilities. • Level 2 – Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs. • Level 3 – Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk. Assets and liabilities measured at fair value on a recurring basis consist of the following as of June 30, 2017 and December 31, 2016 : As of June 30, 2017 December 31, 2016 (in millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market and government funds $ 66 $ — $ — $ 66 $ 42 $ — $ — $ 42 Available-for-sale securities 30 — — 30 20 — — 20 Currency hedge contracts — 96 — 96 — 199 — 199 $ 96 $ 96 $ — $ 192 $ 62 $ 199 $ — $ 261 Liabilities Currency hedge contracts $ — $ 70 $ — $ 70 $ — $ 26 $ — $ 26 Accrued contingent consideration — — 102 102 — — 204 204 $ — $ 70 $ 102 $ 172 $ — $ 26 $ 204 $ 230 Our investments in money market and government funds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices. These investments are classified as cash and cash equivalents within our accompanying unaudited condensed consolidated balance sheets, in accordance with U.S. GAAP and our accounting policies. In addition to $66 million invested in money market and government funds as of June 30, 2017 , we had $129 million in interest bearing and non-interest bearing bank accounts. In addition to $42 million invested in money market and government funds as of December 31, 2016 , we had $19 million in short-term deposits and $135 million in interest bearing and non-interest bearing bank accounts. Our recurring fair value measurements using significant unobservable inputs (Level 3) relate solely to our contingent consideration liability. Refer to Note B – Acquisitions and Strategic Investments for a discussion of the changes in the fair value of our contingent consideration liability. Non-Recurring Fair Value Measurements We hold certain assets and liabilities that are measured at fair value on a non-recurring basis in periods subsequent to initial recognition. The fair value of a cost method investment is not estimated if there are no identified events or changes in circumstances that may have a significant adverse effect on the fair value of the investment. Refer to Note B – Acquisitions and Strategic Investments for a discussion of our strategic investments. The fair value of our outstanding debt obligations was $6.174 billion as of June 30, 2017 and $5.739 billion as of December 31, 2016 , which was determined by using quoted market prices for our publicly registered senior notes, classified as Level 1 within the fair value hierarchy. Refer to Note E – Borrowings and Credit Arrangements for a discussion of our debt obligations.

Borrowings and Credit Arrangeme

Borrowings and Credit Arrangements	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
BORROWINGS AND CREDIT ARRANGEMENTS	NOTE E – BORROWINGS AND CREDIT ARRANGEMENTS We had total debt of $5.835 billion as of June 30, 2017 and $5.484 billion as of December 31, 2016 . The debt maturity schedule for the significant components of our long-term debt obligations as of June 30, 2017 and December 31, 2016 is as follows: in millions, except interest rates Maturity Date June 30, 2017 December 31, 2016 January 2017 5.125% Notes January 2017 $ — $ 250 October 2018 2.650% Notes October 2018 600 600 January 2020 6.000% Notes January 2020 850 850 May 2020 2.850% Notes May 2020 600 600 May 2022 3.375% Notes May 2022 500 500 May 2025 3.850% Notes May 2025 750 750 October 2023 4.125% Notes October 2023 450 450 November 2035 6.250% Notes November 2035 350 350 January 2040 7.375% Notes January 2040 300 300 August 2018 Term Loan August 2018 — 150 August 2020 Term Loan 2018-2020 400 600 Debt discount 2018-2040 (7 ) (8 ) Deferred financing costs 2018-2040 (22 ) (24 ) Interest rate swaps 2020-2023 45 51 Capital lease obligation 2018-2020 1 1 Long-term debt $ 4,817 $ 5,420 Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges. Revolving Credit Facility On April 10, 2015, we entered into a $2.000 billion revolving credit facility (the 2015 Facility) with a global syndicate of commercial banks and terminated our previous $2.000 billion revolving credit facility. The 2015 Facility matures on April 10, 2020. This facility provides backing for the commercial paper program described below. There were no borrowings outstanding under the 2015 Facility as of June 30, 2017 and December 31, 2016 . The 2015 Facility agreement contains normal and customary covenants, interest rates and fees as described in our most recent Annual Report on Form 10-K. As of and through June 30, 2017 , we were in compliance with the required covenants. Commercial Paper In June 2017, we launched a commercial paper program that allows the Company to have a maximum of $2.000 billion in commercial paper outstanding. As of June 30, 2017 there was $1.013 billion of commercial paper outstanding. The commercial paper program is backed by the revolving credit facility. Commercial paper issued as of June 30, 2017 had a weighted average maturity of 23 days and a weighted average yield of 1.7 percent . Term Loans As of June 30, 2017 , we had an aggregate of $400 million outstanding under our unsecured term loan facilities and $750 million outstanding as of December 31, 2016 . These facilities include an unsecured term loan facility maturing August 2018 (August 2018 Term Loan) and an unsecured term loan facility maturing August 2020 (August 2020 Term Loan). The August 2018 Term Loan had $150 million outstanding as of December 31, 2016 and was fully repaid as of June 30, 2017 . The August 2020 Term Loan had $400 million outstanding as of June 30, 2017 and $600 million outstanding as of December 31, 2016 . In July 2017, we fully repaid the $400 million outstanding under the August 2020 Term Loan. Senior Notes We had senior notes outstanding of $4.400 billion as of June 30, 2017 and $4.650 billion as of December 31, 2016 . On January 12, 2017, we used our existing credit facilities to repay the $250 million plus interest of our senior notes due in January 2017. Our senior notes were issued in public offerings, are redeemable prior to maturity and are not subject to any sinking fund requirements. Our senior notes are unsecured, unsubordinated obligations and rank on parity with each other. These notes are effectively junior to borrowings under our credit and security facility and to the extent borrowed by our subsidiaries, to liabilities of our subsidiaries (see Other Arrangements below). Other Arrangements As of December 31, 2016 , we maintained a $300 million credit and security facility secured by our U.S. trade receivables maturing on June 9, 201 7. On February 7, 2017, we amended the terms of this credit and security facility, including increasing the facility size to $400 million and extended the facility maturity to February 2019 . We had no borrowings outstanding under this facility as of June 30, 2017 and $60 million as of December 31, 2016 . We have accounts receivable factoring programs in certain European countries that we account for as sales under FASB ASC Topic 860, Transfers and Servicing . These agreements provide for the sale of accounts receivable to third parties, without recourse, of up to $434 million as of June 30, 2017 . We have no retained interests in the transferred receivables, other than collection and administrative responsibilities and, once sold, the accounts receivable are no longer available to satisfy creditors in the event of bankruptcy. We de-recognized $165 million of receivables as of June 30, 2017 at an average interest rate of 1.8 percent and $152 million as of December 31, 2016 at an average interest rate of 1.8 percent . In addition, we have uncommitted credit facilities with a commercial Japanese bank that provide for borrowings, promissory notes discounting and receivables factoring of up to 22.0 billion Japanese yen (approximately $196 million as of June 30, 2017 ). We de-recognized $157 million of notes receivable and factored receivables as of June 30, 2017 at an average interest rate of 1.3 percent and $149 million of notes receivable as of December 31, 2016 at an average interest rate of 1.6 percent . De-recognized accounts and notes receivable are excluded from trade accounts receivable, net in the accompanying unaudited condensed consolidated balance sheets. As of and through June 30, 2017 , we were in compliance with all the required covenants related to our debt obligations. For additional information regarding the terms of our debt agreements, refer to Note F - Borrowings and Credit Arrangements of the consolidated financial statements in our most recent Annual Report on Form 10-K.

Restructuring Related Activitie

Restructuring Related Activities	6 Months Ended
	Jun. 30, 2017
Restructuring and Related Activities [Abstract]
RESTRUCTURING-RELATED ACTIVITIES	NOTE F – RESTRUCTURING-RELATED ACTIVITIES 2016 Restructuring Plan On June 6, 2016, our Board of Directors approved and we committed to a restructuring initiative (the 2016 Restructuring Plan). The 2016 Restructuring Plan is intended to develop global commercialization, technology and manufacturing capabilities in key growth markets, build on our Plant Network Optimization (PNO) strategy, which is intended to simplify our manufacturing plant structure by transferring certain production lines among facilities and expand operational efficiencies in support of our operating income margin goals. Key activities under the 2016 Restructuring Plan include strengthening global infrastructure through evolving global real estate assets and workplaces, developing global commercial and technical competencies, enhancing manufacturing and distribution expertise in certain regions and continuing implementation of our ongoing PNO strategy. These activities were initiated in the second quarter of 2016 and are expected to be substantially completed by the end of 2018. The 2016 Restructuring Plan is expected to result in total pre-tax charges of approximately $175 million to $225 million and approximately $160 million to $210 million of these charges are estimated to result in cash outlays. We have recorded related costs of $82 million since the inception of the plan through June 30, 2017 and recorded a portion of these expenses as restructuring charges and the remaining portion through other lines within our consolidated statements of operations. The following table provides a summary of our estimates of costs associated with the 2016 Restructuring Plan through the end of 2018 by major type of cost: Type of cost Total estimated amount expected to be incurred Restructuring charges: Termination benefits $60 million to $70 million Other (1) $10 million to $20 million Restructuring-related expenses: Other (2) $105 million to $135 million $175 million to $225 million (1) Consists primarily of consulting fees and costs associated with contract cancellations. (2) Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation and costs to transfer product lines among facilities. We recorded restructuring charges pursuant to our restructuring plans of $1 million in the second quarter of 2017 , $14 million in the second quarter of 2016 , $5 million in the first half of 2017 and $17 million in the first half of 2016 . In addition, we recorded expenses within other lines of our accompanying unaudited condensed consolidated statements of operations related to our restructuring initiatives of $15 million in the second quarter of 2017 , $12 million in the second quarter of 2016 , $30 million in the first half of 2017 and $22 million in the first half of 2016 . The following presents these costs (credits) by major type and line item within our accompanying unaudited condensed consolidated statements of operations: Three Months Ended June 30, 2017 (in millions) Termination Benefits Accelerated Depreciation Transfer Costs Other Total Restructuring charges $ — $ — $ — $ 1 $ 1 Restructuring-related expenses: Cost of products sold — — 12 — 12 Selling, general and administrative expenses — 2 — 1 3 — 2 12 1 15 $ — $ 2 $ 12 $ 2 $ 16 All charges incurred in the second quarter of 2017 were related to the 2016 Restructuring Plan. Three Months Ended June 30, 2016 (in millions) Termination Benefits Accelerated Depreciation Transfer Costs Other Total Restructuring charges $ 14 $ — $ — $ — $ 14 Restructuring-related expenses: Cost of products sold — — 7 — 7 Selling, general and administrative expenses — 3 — 2 5 — 3 7 2 12 $ 14 $ 3 $ 7 $ 2 $ 26 (in millions) Termination Benefits Accelerated Depreciation Transfer Costs Other Total 2016 Restructuring Plan $ 18 $ — $ 1 $ — $ 19 2014 Restructuring Plan (4 ) 3 6 2 7 $ 14 $ 3 $ 7 $ 2 $ 26 Six Months Ended June 30, 2017 (in millions) Termination Benefits Accelerated Depreciation Transfer Costs Other Total Restructuring charges $ 3 $ — $ — $ 2 $ 5 Restructuring-related expenses: Cost of products sold — — 24 — 24 Selling, general and administrative expenses — 3 — 3 6 — 3 24 3 30 $ 3 $ 3 $ 24 $ 5 $ 35 All charges incurred in the first half of 2017 were related to the 2016 Restructuring Plan. Six Months Ended June 30, 2016 (in millions) Termination Accelerated Transfer Other Total Restructuring charges $ 15 $ — $ — $ 2 $ 17 Restructuring-related expenses: Cost of products sold — — 12 — 12 Selling, general and administrative expenses — 4 — 6 10 — 4 12 6 22 $ 15 $ 4 $ 12 $ 8 $ 39 (in millions) Termination Accelerated Transfer Other Total 2016 Restructuring Plan $ 18 $ — $ 1 $ — $ 19 2014 Restructuring Plan (3 ) 4 11 8 20 $ 15 $ 4 $ 12 $ 8 $ 39 Termination benefits represent amounts incurred pursuant to our ongoing benefit arrangements and amounts for “one-time” involuntary termination benefits and have been recorded in accordance with FASB ASC Topic 712 , Compensation - Nonretirement and Postemployment Benefits and FASB ASC Topic 420 , Exit or Disposal Cost Obligations . Other restructuring costs, which represent primarily consulting fees and costs related to contract cancellations, are being recorded as incurred in accordance with FASB ASC Topic 420 . Accelerated depreciation is being recorded over the adjusted remaining useful life of the related assets and program management and production line transfer costs are being recorded as incurred. As of June 30, 2017 , we incurred cumulative restructuring charges related to our 2016 Restructuring Plan of $33 million and restructuring-related charges of $49 million since we committed to the plan. The following presents these costs by major type: (in millions) 2016 Restructuring Plan Termination benefits $ 27 Other 6 Total restructuring charges 33 Accelerated depreciation 5 Transfer costs 39 Other 5 Restructuring-related expenses 49 $ 82 We made cash payments of $33 million in the first half of 2017 associated with our 2016 Restructuring Plan, and as of June 30, 2017 , we had made total cash payments of $60 million related to our 2016 Restructuring Plan since committing to the plan. These payments were made using cash generated from operations and are comprised of the following: (in millions) 2016 Restructuring Plan Six Months Ended June 30, 2017 Termination benefits $ 6 Transfer costs 24 Other 3 $ 33 Program to Date Termination benefits $ 14 Transfer costs 39 Other 7 $ 60 Our restructuring liability is primarily comprised of accruals for termination benefits. The following is a rollforward of the termination benefit liability associated with our 2016 Restructuring Plan, which is reported as a component of accrued expenses included in our accompanying unaudited condensed balance sheets: (in millions) 2016 Restructuring Plan Accrued as of December 31, 2016 $ 16 Charges (credits) 3 Cash payments (6 ) Accrued as of June 30, 2017 $ 13 In addition to our accrual for termination benefits, we had a $7 million liability as of June 30, 2017 and $6 million as of December 31, 2016 for other restructuring-related items.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	6 Months Ended
	Jun. 30, 2017
Supplemental Balance Sheet Information [Abstract]
Supplemental Balance Sheet Disclosures	NOTE G – SUPPLEMENTAL BALANCE SHEET INFORMATION Components of selected captions in our accompanying unaudited condensed consolidated balance sheets are as follows: Trade accounts receivable, net As of (in millions) June 30, 2017 December 31, 2016 Accounts receivable $ 1,564 $ 1,591 Less: allowance for doubtful accounts (74 ) (73 ) Less: allowance for sales returns (46 ) (46 ) $ 1,444 $ 1,472 The following is a rollforward of our allowance for doubtful accounts for the second quarter and first half of 2017 and 2016 : Three Months Ended Six Months Ended (in millions) 2017 2016 2017 2016 Beginning balance $ 75 $ 80 $ 73 $ 75 Net charges to expenses 2 3 5 7 Utilization of allowances (3 ) (3 ) (4 ) (2 ) Ending balance $ 74 $ 80 $ 74 $ 80 Inventories As of (in millions) June 30, 2017 December 31, 2016 Finished goods $ 652 $ 625 Work-in-process 97 94 Raw materials 274 236 $ 1,023 $ 955 Other current assets As of (in millions) June 30, 2017 December 31, 2016 Prepaid expenses $ 91 $ 58 Restricted cash 251 243 Other 143 240 $ 485 $ 541 Property, plant and equipment, net As of (in millions) June 30, 2017 December 31, 2016 Land $ 92 $ 91 Buildings and improvements 1,043 981 Equipment, furniture and fixtures 3,081 2,955 Capital in progress 305 338 4,521 4,365 Less: accumulated depreciation 2,870 2,735 $ 1,651 $ 1,630 Depreciation expense was $65 million for the second quarter of 2017 , $62 million for the second quarter of 2016 , $127 million for the first half of 2017 and $126 million for the first half of 2016 . Accrued expenses As of (in millions) June 30, 2017 December 31, 2016 Legal reserves $ 1,152 $ 1,062 Payroll and related liabilities 486 572 Accrued contingent consideration 39 63 Other 561 615 $ 2,238 $ 2,312 Other long-term liabilities As of (in millions) June 30, 2017 December 31, 2016 Accrued income taxes $ 797 $ 781 Legal reserves 627 961 Accrued contingent consideration 63 141 Other long-term liabilities 485 455 $ 1,972 $ 2,338 Accrued warranties We offer warranties on certain of our product offerings. The majority of our warranty liability relates to implantable devices offered by our Cardiac Rhythm Management (CRM) business, which include defibrillator and pacemaker systems. Our CRM products come with a standard limited warranty covering the replacement of these devices. We offer a full warranty for a portion of the period post-implant and a partial warranty for a period of time thereafter. We estimate the costs that we may incur under our warranty programs based on the number of units sold, historical and anticipated rates of warranty claims and cost per claim and record a liability equal to these estimated costs as cost of products sold at the time the product sale occurs. We reassess the adequacy of our recorded warranty liabilities on a quarterly basis and adjust these amounts as necessary. The current portion of our warranty accrual is included in other accrued expenses in the table above and the non-current portion of our warranty accrual is included in other long-term liabilities in the table above. Changes in our product warranty accrual during the first half of 2017 and 2016 consisted of the following: Six Months Ended (in millions) 2017 2016 Beginning Balance $ 22 $ 23 Provision 13 10 Settlements/reversals (13 ) (13 ) Ending Balance $ 22 $ 20

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE H – INCOME TAXES Our effective tax rate from continuing operations was (60.3) percent for the second quarter of 2017 as compared to 47.8 percent for the second quarter of 2016 . For the first half of 2017 , our effective tax rate from continuing operations was (10.1) percent , as compared to 97.0 percent for the first half of 2016 . The change in our reported tax rates for the second quarter and first half of 2017 , as compared to the same periods in 2016 , relates primarily to the impact of certain receipts and charges that are taxed at different rates than our effective tax rate, including acquisition-related items, contingent consideration, restructuring and restructuring-related items, investment impairment-related items, litigation-related items and amortization expense, as well as the impact of certain discrete tax items. As of June 30, 2017 , we had $1.116 billion of gross unrecognized tax benefits, of which a net $1.027 billion , if recognized, would affect our effective tax rate. As of December 31, 2016 , we had $1.095 billion of gross unrecognized tax benefits, of which a net $1.006 billion , if recognized, would affect our effective tax rate. We have received Notices of Deficiency from the Internal Revenue Service (IRS) reflecting proposed audit adjustments for Guidant Corporation for its 2001 through 2006 tax years and for Boston Scientific Corporation for its 2006 and 2007 tax years. The total incremental tax liability asserted by the IRS for the applicable periods is $1.162 billion plus interest. The primary issue in dispute for all years is the transfer pricing associated with the technology license agreements between domestic and foreign subsidiaries of Guidant. In addition, the IRS has proposed adjustments in connection with the financial terms of our Transaction Agreement with Abbott Laboratories pertaining to the sale of Guidant's vascular intervention business to Abbott in April 2006. During 2014, we received a Revenue Agent Report from the IRS reflecting significant proposed audit adjustments to our 2008, 2009 and 2010 tax years based upon the same transfer pricing methodologies that the IRS applied to our 2001 through 2007 tax years. We do not agree with the transfer pricing methodologies applied by the IRS or its resulting assessment. We have filed petitions with the U.S. Tax Court (Tax Court) contesting the Notices of Deficiency for the 2001 through 2007 tax years in challenge and submitted a letter to the IRS Office of Appeals (IRS Appeals) protesting the Revenue Agent Report for the 2008 through 2010 tax years and requesting an administrative appeal hearing. The issues in dispute were scheduled to be heard in Tax Court in late July 2016. On July 19, 2016, we entered into a Stipulation of Settled Issues with the IRS intended to resolve all of the aforementioned transfer pricing issues, as well as the issues related to our transaction with Abbott, for the 2001 through 2007 tax years. The Stipulation of Settled Issues is contingent upon IRS Office of Appeals applying the same basis of settlement to all transfer pricing issues for the Company’s 2008, 2009 and 2010 tax years and if applicable, review by the United States Congress Joint Committee on Taxation. In October 2016, we reached an agreement in principle with the IRS Appeals as to the resolution of transfer pricing issues in 2008, 2009 and 2010 tax years, subject to additional calculations of tax as well as documentation to memorialize our agreement. In the event that the conditions in the Stipulation of Settled Items are satisfied, we expect to make net tax payments of approximately $275 million , plus interest, through the date of payment. If finalized, payments related to the resolution are expected in the next three to nine months. We believe that our income tax reserves associated with these matters are adequate as of June 30, 2017 and we do not expect to recognize any additional charges related to the resolution of this controversy. However, the final resolution of these issues is contingent and if the Stipulation of Settled Issues is not finalized, it could have a material impact on our financial condition, results of operations, or cash flows. We recognize interest and penalties related to income taxes as a component of income tax expense. We had $612 million accrued for gross interest and penalties as of June 30, 2017 and $572 million as of December 31, 2016 . We recognized net tax expense related to interest and penalties of $13 million during the second quarter of 2017 and the second quarter of 2016 , $26 million during the first half of 2017 and $23 million during the first half of 2016 . It is reasonably possible that within the next 12 months we will resolve multiple issues including transfer pricing and transactional-related issues with foreign, federal and state taxing authorities, in which case we could record a reduction in our balance of unrecognized tax benefits of up to approximately $757 million .

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE I – COMMITMENTS AND CONTINGENCIES The medical device market in which we primarily participate is largely technology driven. As a result, intellectual property rights, particularly patents and trade secrets, play a significant role in product development and differentiation. Over the years, there has been litigation initiated against us by others, including our competitors, claiming that our current or former product offerings infringe patents owned or licensed by them. Intellectual property litigation is inherently complex and unpredictable. In addition, competing parties frequently file multiple suits to leverage patent portfolios across product lines, technologies and geographies and to balance risk and exposure between the parties. In some cases, several competitors are parties in the same proceeding or in a series of related proceedings or litigate multiple features of a single class of devices. These forces frequently drive settlement not only for individual cases, but also for a series of pending and potentially related and unrelated cases. Although monetary and injunctive relief is typically sought, remedies and restitution are generally not determined until the conclusion of the trial court proceedings and can be modified on appeal. Accordingly, the outcomes of individual cases are difficult to time, predict or quantify and are often dependent upon the outcomes of other cases in other geographies. During recent years, we successfully negotiated closure of several long-standing legal matters and have received favorable rulings in several other matters, however, there continues to be outstanding intellectual property litigation. Adverse outcomes in one or more of these matters could have a material adverse effect on our ability to sell certain products and on our operating margins, financial position, results of operations and/or liquidity. In the normal course of business, product liability, securities and commercial claims are asserted against us. Similar claims may be asserted against us in the future related to events not known to management at the present time. We maintain an insurance policy providing limited coverage against securities claims and we are substantially self-insured with respect to product liability claims and fully self-insured with respect to intellectual property infringement claims. The absence of significant third-party insurance coverage increases our potential exposure to unanticipated claims or adverse decisions. Product liability claims, securities and commercial litigation and other legal proceedings in the future, regardless of their outcome, could have a material adverse effect on our financial position, results of operations and/or liquidity. In addition, like other companies in the medical device industry, we are subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which we operate. From time to time we are the subject of qui tam actions and governmental investigations often involving regulatory, marketing and other business practices. These qui tam actions and governmental investigations could result in the commencement of civil and criminal proceedings, substantial fines, penalties and administrative remedies and have a material adverse effect on our financial position, results of operations and/or liquidity. In accordance with FASB ASC Topic 450, Contingencies , we accrue anticipated costs of settlements, damages and losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range. Our accrual for legal matters that are probable and estimable was $1.779 billion as of June 30, 2017 and $2.023 billion as of December 31, 2016 and includes certain estimated costs of settlement, damages and defense. We recorded $208 million of litigation-related charges during the first half of 2017 and $628 million of litigation-related charges during the first half of 2016 . The net charges recorded in the first half of 2017 and 2016 primarily include amounts related to transvaginal surgical mesh product liability cases and claims. We continue to assess certain litigation and claims to determine the amounts, if any, that management believes will be paid as a result of such claims and litigation and, therefore, additional losses may be accrued and paid in the future, which could materially adversely impact our operating results, cash flows and/or our ability to comply with our debt covenants. In management's opinion, we are not currently involved in any legal proceedings other than those disclosed in our most recent Annual Report on Form 10-K, our Quarterly Report on Form 10-Q for the Quarter ended March 31, 2017, and those specifically identified below, which, individually or in the aggregate, could have a material adverse effect on our financial condition, operations and/or cash flows. Unless included in our legal accrual or otherwise indicated below, a range of loss associated with any individual material legal proceeding cannot be estimated. Patent Litigation On November 29, 2016 Nevro Corp. (“Nevro”) filed a patent infringement action against us and one of our subsidiaries, Boston Scientific Neuromodulation Corporation, in the United States District Court for the Northern District of California alleging that six U.S. patents (Alataris) owned by Nevro are infringed by our spinal cord stimulation systems. On June 29, 2017, Nevro amended the complaint to add an additional patent (Fang). We deny the plaintiff's allegations and intend to defend ourselves vigorously. Product Liability Litigation As of July 26, 2017 , approximately 48,000 product liability cases or claims related to transvaginal surgical mesh products designed to treat stress urinary incontinence and pelvic organ prolapse have been asserted against us. The pending cases are in various federal and state courts in the United States and include eight putative class actions. There were also fewer than 20 cases in Canada, inclusive of one certified and three putative class actions, and fewer than 25 claims in the United Kingdom. Generally, the plaintiffs allege personal injury associated with use of our transvaginal surgical mesh products. The plaintiffs assert design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. Over 3,100 of the cases have been specially assigned to one judge in state court in Massachusetts. On February 7, 2012, the Judicial Panel on Multi-District Litigation (MDL) established MDL-2326 in the United States District Court for the Southern District of West Virginia and transferred the federal court transvaginal surgical mesh cases to MDL-2326 for coordinated pretrial proceedings. During the fourth quarter of 2013, we received written discovery requests from certain state attorneys general offices regarding our transvaginal surgical mesh products. We have responded to those requests. As of July 26, 2017 , we have entered into master settlement agreements in principle or are in final stages of entering one with certain plaintiffs' counsel to resolve an aggregate of approximately 38,000 cases and claims. These master settlement agreements provide that the settlement and distribution of settlement funds to participating claimants are conditional upon, among other things, achieving minimum required claimant participation thresholds. Of the approximately 38,000 cases and claims, approximately 14,500 have met the conditions of the settlement and are final. All settlement agreements were entered into solely by way of compromise and without any admission or concession by us of any liability or wrongdoing. On or about January 12, 2016, Teresa L. Stevens filed a claim against us and three other defendants asserting for herself and on behalf of a putative class of similarly-situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the United States District Court for the Southern District of West Virginia, before the same Court that is hearing the mesh MDL. The complaint, which alleges Racketeer Influenced and Corrupt Organizations Act (RICO) violations, fraud, misrepresentation, deceptive trade practices and unjust enrichment, seeks both equitable relief and damages under state and federal law. On January 26, 2016, the Court issued an order staying the case and directing the plaintiff to submit information to allow the FDA to issue a determination with respect to her allegations. In addition, we are in contact with the United States Attorney’s Office for the Southern District of West Virginia and are responding voluntarily to their requests in connection with that office’s review of the allegations concerning the use of mesh resin in the complaint. We deny the plaintiff’s allegations and intend to defend ourselves vigorously. On February 27, 2017, Carolyn Turner filed a complaint against us and five other defendants asserting for herself and on behalf of a putative class of similarly situated women, that she was harmed by a vaginal mesh implant that she alleges contained a counterfeit or adulterated resin product that we imported from China. The complaint was filed in the United States District Court for the Middle District of Florida, Orlando Division and alleges violations of the Racketeer Influenced and Corrupt Organizations Act (RICO), negligence, strict liability, breach of an express or implied warranty, intentional and negligent misrepresentation, fraud and unjust enrichment. Ms. Turner served this complaint against the Company on April 7, 2017. As of April 27, 2017, this case has been stayed, pending resolution of the transfer petition to the mesh multidistrict litigation. We deny the plaintiff’s allegations and intend to defend ourselves vigorously. We have established a product liability accrual for known and estimated future cases and claims asserted against us as well as with respect to the actions that have resulted in verdicts against us and the costs of defense thereof associated with our transvaginal surgical mesh products. While we believe that our accrual associated with this matter is adequate, changes to this accrual may be required in the future as additional information becomes available. While we continue to engage in discussions with plaintiffs’ counsel regarding potential resolution of pending cases and claims and intend to vigorously contest the cases and claims asserted against us that do not settle, the final resolution of the cases and claims is uncertain and could have a material impact on our results of operations, financial condition and/or liquidity. Initial trials involving our transvaginal surgical mesh products have resulted in both favorable and unfavorable judgments for us. We do not believe that the judgment in any one trial is representative of potential outcomes of all cases or claims related to our transvaginal surgical mesh products. Governmental Investigations and Qui Tam Matters On August 3, 2012, we were served with a qui tam complaint that had previously been filed under seal against Boston Scientific Neuromodulation Corp. in the U.S. District Court for the District of New Jersey on March 2, 2011. On August 8, 2012, we learned that the federal government had previously declined to intervene in this matter. The relators’ complaint, now unsealed, alleges that Boston Scientific Neuromodulation Corp. violated the federal and various states' false claims acts through submission of fraudulent bills for implanted devices, under-reporting of certain adverse events, and promotion of off-label uses. On September 10, 2012, the relators filed an amended complaint revising and restating certain of the claims in the original complaint. Our motion to dismiss, filed subsequently, was denied on May 31, 2013, and on June 28, 2013, we answered the amended complaint and brought certain counterclaims arising from relators’ unauthorized removal of documents from the business during their employments, which the relators moved to dismiss on July 22, 2013. The Court denied relators’ motion to dismiss the counterclaims on September 4, 2014. Following the completion of fact and expert discovery, we filed a motion for summary judgment against all claims on January 27, 2017; relators filed their own motion for summary judgment against our counterclaims that same date; and the parties await the Court’s rulings on the motions. On December 1, 2015, the Brazilian governmental entity known as CADE (the Administrative Council of Economic Defense), served a search warrant on the offices of our Brazilian subsidiary, as well as on the Brazilian offices of several other major medical device makers who do business in Brazil, in furtherance of an investigation into alleged anti-competitive activity with respect to certain tender offers for government contracts. On June 20, 2017, CADE, through the publication of a “technical note,” announced that it was launching a formal administrative proceeding against Boston Scientific’s Brazilian subsidiary, Boston Scientific do Brasil Ltda., as well as against the Brazilian operations of Medtronic, Biotronik, and St. Jude Medical, two Brazilian associations, ABIMED and AMBIMO, and 29 individuals for alleged anti-competitive behavior. We deny the allegations and intend to defend ourselves vigorously. On December 14, 2016, we learned that the Associacao Brasileira de Medicina de Grupo d/b/a ABRAMGE filed a complaint against the Company, Arthrex and Zimmer Biomet Holdings, in the United States District Court for the District of Delaware. This complaint, which ABRAMGE never served against the Company, alleges that the defendants or their agents paid kickbacks to health care providers in order to increase sales and prices and are liable under a variety of common law theories. On February 6, 2017, ABRAMGE filed and served an amended complaint on the Company and the other defendants. The amended complaint does not contain any material changes in the allegations against the Company. Subsequently, on March 2, 2017, ABRAMGE filed a motion to consolidate this lawsuit with two other similar suits that it had brought against Stryker and Abbott Laboratories, in a multidistrict litigation proceeding. On April 13, 2017, we filed a motion to dismiss the amended complaint, as well as a separate opposition to the multidistrict litigation motion, and on May 31, 2017, the Joint Panel on Multi-District Litigation denied ABRAMGE’s motion for the multidistrict litigation. Other Proceedings On November 2, 2015, Acacia Research Corporation (ARC) filed an arbitration demand with the American Arbitration Association alleging that the Company breached an agreement relating to the sale of patents from the Company to ARC. The hearing began on February 20, 2017. On May 12, 2017 the arbitrators reached a confidential decision.

Weighted Average Shares Outstan

Weighted Average Shares Outstanding	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Weighted Average Number Of Shares Outstanding [Text Block]	NOTE J – WEIGHTED AVERAGE SHARES OUTSTANDING Three Months Ended Six Months Ended (in millions) 2017 2016 2017 2016 Weighted average shares outstanding - basic 1,369.8 1,357.4 1,367.6 1,353.9 Net effect of common stock equivalents 21.3 — * 23.0 — * Weighted average shares outstanding - assuming dilution 1,391.1 1,357.4 1,390.6 1,353.9 *We generated net losses in the second quarter and first half of 2016 . Our weighted-average shares outstanding for earnings per share calculations exclude common stock equivalents of 17.7 million for the second quarter of 2016 and 18.6 million for the first half of 2016 due to our net loss positions. The impact of stock options outstanding with exercise prices greater than the average fair market value of our common stock was immaterial for all periods presented. We issued approximately one million shares of our common stock in the second quarter of 2017 , four million shares of our common stock in the second quarter of 2016 , eight million shares of our common stock in the first half of 2017 and 12 million shares of our common stock in the first half of 2016 , following the exercise of underlying stock options, vesting of deferred stock units or purchases under our employee stock purchase plan. We did not repurchase any shares of our common stock during the first half of 2017 or 2016 .

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
SEGMENT REPORTING	NOTE K – SEGMENT REPORTING We have three reportable segments comprised of Cardiovascular, Rhythm Management and MedSurg, which represent an aggregation of our operating segments. Each of our reportable segments generates revenue from the sale of medical devices. We measure and evaluate our reportable segments based on segment net sales and operating income, excluding the impact of changes in foreign currency. Sales generated from reportable segments, as well as operating results of reportable segments and corporate expenses, are calculated based on internally-derived standard currency exchange rates, which may differ from year to year and do not include intersegment profits. We restated segment information for the prior period based on our internally-derived standard currency exchange rates as of January 1, 2017, used for the current period in order to remove the impact of foreign currency exchange fluctuation. We exclude from segment operating income certain corporate-related expenses and certain transactions or adjustments that our chief operating decision maker considers to be non-operational, such as acquisition-related, restructuring- and restructuring-related, and litigation-related net credits and charges, and amortization expense. Although we exclude these amounts from segment operating income, they are included in reported consolidated operating income (loss) and are included in the reconciliation below. A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows: Three Months Ended Six Months Ended (in millions) 2017 2016 2017 2016 (restated) (restated) Net sales Interventional Cardiology $ 612 $ 580 $ 1,217 $ 1,140 Peripheral Interventions 277 260 545 508 Cardiovascular 889 840 1,762 1,648 Cardiac Rhythm Management 484 476 956 915 Electrophysiology 67 60 133 120 Rhythm Management 551 536 1,089 1,035 Endoscopy 405 361 792 700 Urology and Pelvic Health 282 255 546 485 Neuromodulation 154 135 296 257 MedSurg 841 751 1,634 1,442 Net sales allocated to reportable segments 2,281 2,127 4,485 4,125 Impact of foreign currency fluctuations (24 ) (1 ) (67 ) (35 ) $ 2,257 $ 2,126 $ 4,418 $ 4,090 Income (loss) before income taxes Cardiovascular $ 268 $ 249 $ 513 $ 503 Rhythm Management 115 73 216 140 MedSurg 270 234 508 448 Operating income allocated to reportable segments 653 556 1,237 1,091 Corporate expenses and currency exchange (66 ) (58 ) (153 ) (99 ) Acquisition-related, restructuring- and restructuring-related, and litigation-related net credits (charges) (220 ) (697 ) (210 ) (762 ) Amortization expense (142 ) (135 ) (285 ) (271 ) Operating income (loss) 225 (334 ) 589 (41 ) Other expense, net (134 ) (63 ) (193 ) (128 ) Income (loss) before income taxes $ 91 $ (397 ) $ 396 $ (169 )

Changes in Other Comprehensive

Changes in Other Comprehensive Income	6 Months Ended
	Jun. 30, 2017
Changes in Other Comprehensive Income [Abstract]
Comprehensive Income (Loss) Note [Text Block]	NOTE L – CHANGES IN OTHER COMPREHENSIVE INCOME The following table provides the reclassifications out of other comprehensive income for the three and six months ended June 30, 2017 and June 30, 2016 . Amounts in the chart below are presented net of tax. Three Months Ended June 30, 2017 (in millions) Foreign Currency Translation Adjustments Unrealized Gains/Losses on Derivative Financial Instruments Unrealized Gains/Losses on Available-for-Sale Securities Defined Benefit Pension Items / Other Total Balance as of March 31, 2017 $ (71 ) $ 52 $ (6 ) $ (21 ) $ (46 ) Other comprehensive income (loss) before reclassifications 13 (4 ) — — 9 Amounts reclassified from accumulated other comprehensive income — (17 ) 2 (1 ) (16 ) Net current-period other comprehensive income 13 (21 ) 2 (1 ) (7 ) Balance as of June 30, 2017 $ (58 ) $ 31 $ (4 ) $ (22 ) $ (53 ) Three Months Ended June 30, 2016 (in millions) Foreign Currency Translation Adjustments Unrealized Gains/Losses on Derivative Financial Instruments Defined Benefit Pension Items / Other Total Balance as of March 31, 2016 $ (38 ) $ 83 $ (10 ) $ 35 Other comprehensive income (loss) before reclassifications (21 ) (64 ) (1 ) (86 ) Amounts reclassified from accumulated other comprehensive income — (20 ) 1 (19 ) Net current-period other comprehensive income (21 ) (84 ) — (105 ) Balance as of June 30, 2016 $ (59 ) $ (1 ) $ (10 ) $ (70 ) Six Months Ended June 30, 2017 (in millions) Foreign Currency Translation Adjustments Unrealized Gains/Losses on Derivative Financial Instruments Unrealized Gains/Losses on Available-for-Sale Securities Defined Benefit Pension Items / Other Total Balance as of December 31, 2016 $ (79 ) $ 107 $ (6 ) $ (21 ) $ 1 Other comprehensive income (loss) before reclassifications 21 (41 ) — (2 ) (22 ) Amounts reclassified from accumulated other comprehensive income — (35 ) 2 1 (32 ) Net current-period other comprehensive income 21 (76 ) 2 (1 ) (54 ) Balance as of June 30, 2017 $ (58 ) $ 31 $ (4 ) $ (22 ) $ (53 ) Six Months Ended June 30, 2016 (in millions) Foreign currency translation adjustments Unrealized gains/losses on derivative financial instruments Defined benefit pension items / Other Total Balance as of December 31, 2015 $ (54 ) $ 152 $ (10 ) $ 88 Other comprehensive income (loss) before reclassifications (5 ) (102 ) (3 ) (110 ) Amounts reclassified from accumulated other comprehensive income — (51 ) 3 (48 ) Net current-period other comprehensive income (5 ) (153 ) — (158 ) Balance as of June 30, 2016 $ (59 ) $ (1 ) $ (10 ) $ (70 ) The income tax impact of the amounts in other comprehensive income for unrealized gains and losses on derivative financial instruments before reclassifications was a benefit of $2 million in the second quarter of 2017 , and a benefit of $36 million in the second quarter of 2016 , a benefit of $23 million in the first half of 2017 and a benefit of $57 million in the first half of 2016 . The gains and losses on derivative financial instruments reclassified were reduced by income tax impacts of $10 million in the second quarter of 2017 , $12 million in the second quarter of 2016 , $20 million in the first half of 2017 and $29 million in the first half of 2016 . Refer to Note D – Fair Value Measurements in this Quarterly Report on Form 10-Q for further detail on the reclassifications related to derivatives. The income tax impact of the amounts in other comprehensive income for defined benefit and pension items before reclassification was immaterial in both the second quarter of 2017 and the second quarter of 2016 , and for both the first half of 2017 and 2016 . The gains and losses on defined benefit and pension related items reclassified from accumulated other comprehensive income were reduced by immaterial income tax impacts in the second quarter and first half of 2017 and the second quarter of 2016 and first half of 2016 . The gains and losses on available-for-sale securities were reduced by immaterial income tax impacts for both the second quarter and first half of 2017 .

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	NOTE M – NEW ACCOUNTING PRONOUNCEMENTS From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies. Recently issued standards typically do not require adoption until a future effective date. Prior to their effective date, we evaluate the pronouncements to determine the potential effects of adoption on our condensed consolidated financial statements. Standards Implemented since December 31, 2016 ASC Update No. 2016-09 In March 2016, the FASB issued ASC Update No. 2016-09, Compensation - Stock Compensation (Topic 718) : Improvements to Employee Share-Based Payment Accounting . The purpose of Update No. 2016-09 is to simplify accounting for share-based payment transactions, such as, the accounting for income taxes, statutory tax withholding requirements, forfeitures and statement of cash flow presentation. Update No. 2016-09 was effective for annual periods beginning after December 15, 2016, including interim periods within those annual periods. We adopted Update No. 2016-09 prospectively in the first quarter of 2017 and, as such, no prior periods were adjusted. We previously recorded income tax benefits or deficiencies to additional paid-in capital; however, Update No. 2016-09 requires that all tax benefits or deficiencies be recorded to the provision for income taxes. In the first quarter of 2017, we recorded an income tax benefit of $28 million , which we expect represents the majority of excess tax benefits in 2017 due to the annual vesting of our awards during the first quarter. The actual impact to future periods will depend on the price of our stock, number of stock options exercised and other factors that are difficult to predict. In the first quarter of 2017, a cumulative effect adjustment of $76 million was recorded to retained earnings upon adoption for windfall tax benefits not previously recognized. ASC Update No. 2016-17 In October 2016, the FASB issued ASC Update No. 2016-17, Consolidation (Topic 810) : Interests Held through Related Parties That Are under Common Control . The purpose of Update No. 2016-17 is to amend the consolidation guidance from Update No. 2015-02 on how a reporting entity that is the single decision maker of a variable interest entity (VIE) should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that VIE. The amendment requires that a single decision maker include those indirect interests held through related parties that are under common control with the single decision maker on a proportionate basis consistent with indirect interests held through other related parties. Update No. 2016-17 was effective for annual periods beginning after December 15, 2016, including interim periods within those annual periods. We adopted Update No. 2016-17 in the first quarter of 2017. The adoption of Update No. 2016-17 did not have a material impact on our financial position or results of operations. ASC Update No. 2016-19 In December 2016, the FASB issued ASC Update No. 2016-19, Technical Corrections and Improvements. The purpose of Update No. 2016-19 is to clarify or correct unintended applications of guidance that affects a wide variety of topics in the ASC. Most of the amendments in this Update did not require transition guidance and were effective immediately. Six amendments in this update clarified guidance or corrected references in the ASC and were effective for annual periods beginning after December 15, 2016, including interim periods within these annual periods. We adopted these amendments in the first quarter of 2017. The adoption of Update No. 2016-19 did not have a material impact on our financial position or results of operations. ASC Update No. 2017-04 In January 2017, the FASB issued ASC Update No. 2017-04, Intangibles - Goodwill and Other Topics (Topic 350) : Simplifying the Test for Goodwill Impairment . The purpose of Update No. 2017-04 is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the impaired fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this amendment, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit's fair value. We elected to early adopt Update No. 2017-04 prospectively in the first quarter of 2017. The adoption of Update No. 2017-04 did not have a material impact on our financial position or results of operations. Standards to be Implemented ASC Update No. 2014-09 In May 2014, the FASB issued ASC Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), which has been subsequently updated. The purpose of Update No. 2014-09 is to provide enhancements to the quality and consistency of how revenue is reported while also improving comparability in the financial statements of companies using U.S. GAAP and International Financial Reporting Standards. The core principle requires entities to recognize revenue in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration an entity expects to be entitled to in exchange for those goods or services. FASB ASC Topic 606 , as amended, becomes effective for annual periods beginning after December 15, 2017, at which point we plan to adopt the standard. We currently plan to adopt the standard using the “modified retrospective method.” Under that method, we will apply the rules to contracts that are not completed as of January 1, 2018, and recognize the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. We have reached conclusions on our key accounting assessments related to the standard and are finalizing our accounting policies. Based on our initial assessment, we believe the timing of revenue recognition for our primary revenue stream, single-use medical device sales, will not materially change. We are still finalizing our accounting policies related to variable consideration and assessing disclosure requirements. Upon adopting FASB ASC Topic 606 , we will provide additional disclosures in the notes to the consolidated financial statements, specifically related to disaggregated revenue, contract balances and performance obligations. In 2017, we are implementing new internal controls as part of our efforts to adopt the new revenue recognition standard. These internal controls include providing global training to our finance team and holding regular meetings with management and the Audit Committee to review and approve key decisions. Upon adoption, we expect to implement new internal controls related to our accounting policies and procedures. We will require new internal controls to address risks associated with applying the five-step model, specifically related to judgments made in connection to variable consideration and applying the constraint. Additionally, we will establish monitoring controls to identify new sales arrangements and changes in our business environment that could impact our current accounting assessment. During the second half of 2017, we expect to finalize our impact assessment and redesign impacted processes, policies and controls. ASC Update No. 2016-01 In January 2016, the FASB issued ASC Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10) : Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to other comprehensive income. It requires entities to measure equity investments that do not result in consolidation and are not accounted for under the equity method at fair value with changes recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. It simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. It also requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset and liability. Update No. 2016-01 is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. Early application of certain provisions is permitted. We are unable to determine the effect that the adoption will have on our financial position and results of operations, as it will depend on the equity investments at the adoption date and their future performance. ASC Update No. 2016-02 In February 2016, the FASB issued ASC Update No. 2016-02, Leases (Topic 842) . The purpose of Update No. 2016-02 is to increase the transparency and comparability among organizations by recognizing lease asset and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Update No. 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual. Early application is permitted. We are in the process of determining the effect that the adoption will have on our financial position and results of operations. ASC Update No. 2016-13 In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326) : Measurement of Credit Losses on Financial Instruments . The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early application is permitted for annual periods beginning after December 15, 2018. We are in the process of determining the effect that the adoption will have on our financial position and results of operations. ASC Update No. 2016-15 In August 2016, the FASB issued ASC Update No. 2016-15, Statement of Cash Flows (Topic 230) : Classification of Certain Cash Receipts and Cash Payments. The purpose of Update No. 2016-15 is to reduce the diversity in practice in presentation and classification of the following items within the statement of cash flows: debt prepayments, or debt extinguishment costs, settlement of zero coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investments and beneficial interests in securitization transactions. It also addresses classification of transactions that have characteristics of more than one class of cash flows. Update No. 2016-15 is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. Early adoption is permitted, including application in an interim period. We are in the process of determining the effect that the adoption will have on our consolidated statements of cash flows. ASC Update No. 2016-16 In October 2016, the FASB issued ASC Update No. 2016-16, Income Taxes (Topic 740) : Intra-Entity Transfers of Assets Other Than Inventory . The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. Early application is permitted as of the beginning of an annual period for which financial statements have not been issued or made available for issuance. We are in the process of determining the effect that the adoption will have on our financial position and results of operations. ASC Update No. 2016-18 In November 2016, the FASB issued ASC Update No. 2016-18, Statement of Cash Flows (Topic 230) : Restricted Cash. The purpose of Update No. 2016-18 is to clar ify guidance and presentation related to restricted cash in the statement of cash flows as well as increased disclosure requirements. It requires beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include cash and cash equivalents as well as restricted cash and restricted cash equivalents . Update No. 2016-18 is effective for annual periods beginning after December 15, 2017, including interim reporting periods within those annual periods. Early application is permitted. We are in the process of determining the effect the adoption will have on our consolidated statements of cash flows. ASC Update No. 2017-01 In January 2017, the FASB issued ASC Update No. 2017-01, Business Combinations (Topic 805) : Clarifying the Definition of a Business . The purpose of Update No. 2017-01 is to change the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. Update No. 2017-01 is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. Early adoption is permitted as of the beginning of an annual or interim period for which financial statements have not been issued or made available for issuance. The adoption of Update No. 2017-01 is not expected to have a material impact on our financial position or results of operations. ASC Update No. 2017-09 In May 2017, the FASB issued ASC Update No. 2017-09, Compensation - Stock Compensation (Topic 718) : Scope of Modification Accounting . The purpose of Update No. 2017-09 is to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. Update No. 2017-09 is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. Early application is permitted as of the beginning of an annual or interim period for which financial statements have not been issued or made available for issuance. The adoption of Update No. 2017-09 is not expected to have a material impact on our financial position or results of operations. ASC Update No. 2017-10 In May 2017, the FASB issued ASC Update No. 2017-10, Service Concession Arrangements (Topic 853) : Determining the Customer of the Operation Services (a consensus of the FASB Emerging Issues Task Force) . The purpose of Update No. 2017-10 is to address the diversity in practice as to how an operating entity determines the customer of the operation services in a service concession agreement. Update No. 2017-10 is effective the same time as FASB ASC Topic 606 and requires the same transition method elected for FASB ASC Topic 606 . The adoption of Update No. 2017-10 is not expected to have a material impact on our financial position or results of operations. No other new accounting pronouncements, issued or effective, during the period had, or are expected to have, a material impact on our condensed consolidated financial statements.

Goodwill and Other Intangible20

Goodwill and Other Intangible Assets Goodwill (Policies)	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Our technology-related intangible assets that are not subject to amortization represent technical processes, intellectual property and/or institutional understanding acquired through business combinations that are fundamental to the on-going operations of our business and have no limit to their useful life. Our technology-related intangible assets that are not subject to amortization are comprised primarily of certain acquired balloon and other technology, which is foundational to our continuing operations within the Cardiovascular market and other markets within interventional medicine. We assess our indefinite-lived intangible assets at least annually for impairment and reassess their classification as indefinite-lived assets. We assess qualitative factors to determine whether the existence of events and circumstances indicate that it is more likely than not that our indefinite-lived intangible assets are impaired. If we conclude that it is more likely than not that the asset is impaired, we then determine the fair value of the intangible asset and perform the quantitative impairment test by comparing the fair value with the carrying value in accordance with FASB ASC Topic 350, Intangibles - Goodwill and Other .

Fair Value Measurements Fair Va

Fair Value Measurements Fair Value Measurements (Policies)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurement, Policy [Policy Text Block]	FASB ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures , by considering the estimated amount we would receive or pay to transfer these instruments at the reporting date and by taking into account current interest rates, foreign currency exchange rates, the creditworthiness of the counterparty for the assets and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability, and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of June 30, 2017 , we have classified all of our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by FASB ASC Topic 820 , as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.
Derivatives, Policy [Policy Text Block]	We address market risk from changes in foreign currency exchange rates and interest rates through a risk management program that includes the use of derivative financial instruments and we operate the program pursuant to documented corporate risk management policies. Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives generally offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to FASB ASC Topic 815 , Derivatives and Hedging .

Restructuring Related Activit22

Restructuring Related Activities Restructuring Related Activities (Policies)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Restructuring and Related Activities [Abstract]
Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]	Termination benefits represent amounts incurred pursuant to our ongoing benefit arrangements and amounts for “one-time” involuntary termination benefits and have been recorded in accordance with FASB ASC Topic 712 , Compensation - Nonretirement and Postemployment Benefits and FASB ASC Topic 420 , Exit or Disposal Cost Obligations . Other restructuring costs, which represent primarily consulting fees and costs related to contract cancellations, are being recorded as incurred in accordance with FASB ASC Topic 420 . Accelerated depreciation is being recorded over the adjusted remaining useful life of the related assets and program management and production line transfer costs are being recorded as incurred.	2

Commitments and Contingencies C

Commitments and Contingencies Commitments and Contingencies (Policies)	6 Months Ended
	Jun. 30, 2017
Commitments and Contingencies Disclosure [Abstract]
Legal Costs, Policy [Policy Text Block]	In accordance with FASB ASC Topic 450, Contingencies , we accrue anticipated costs of settlements, damages and losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Accounting Policies [Abstract]
ASC Update No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting [Policy Text Block]	ASC Update No. 2017-09 In May 2017, the FASB issued ASC Update No. 2017-09, Compensation - Stock Compensation (Topic 718) : Scope of Modification Accounting . The purpose of Update No. 2017-09 is to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. Update No. 2017-09 is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. Early application is permitted as of the beginning of an annual or interim period for which financial statements have not been issued or made available for issuance. The adoption of Update No. 2017-09 is not expected to have a material impact on our financial position or results of operations.
ASC Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business [Policy Text Block]	ASC Update No. 2017-01 In January 2017, the FASB issued ASC Update No. 2017-01, Business Combinations (Topic 805) : Clarifying the Definition of a Business . The purpose of Update No. 2017-01 is to change the definition of a business to assist entities with evaluating when a set of transferred assets and activities is a business. Update No. 2017-01 is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. Early adoption is permitted as of the beginning of an annual or interim period for which financial statements have not been issued or made available for issuance. The adoption of Update No. 2017-01 is not expected to have a material impact on our financial position or results of operations.
ASC Update No. 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash [Policy Text Block]	ASC Update No. 2016-18 In November 2016, the FASB issued ASC Update No. 2016-18, Statement of Cash Flows (Topic 230) : Restricted Cash. The purpose of Update No. 2016-18 is to clar ify guidance and presentation related to restricted cash in the statement of cash flows as well as increased disclosure requirements. It requires beginning-of-period and end-of-period total amounts shown on the statement of cash flows to include cash and cash equivalents as well as restricted cash and restricted cash equivalents . Update No. 2016-18 is effective for annual periods beginning after December 15, 2017, including interim reporting periods within those annual periods. Early application is permitted. We are in the process of determining the effect the adoption will have on our consolidated statements of cash flows.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events We evaluate events occurring after the date of our most recent accompanying unaudited condensed consolidated balance sheets for potential recognition or disclosure in our financial statements. We did not identify any material subsequent events requiring adjustment to our accompanying unaudited condensed consolidated financial statements (recognized subsequent events) for the three and six months ended June 30, 2017 . Those items requiring disclosure (unrecognized subsequent events) in the financial statements have been disclosed accordingly. Refer to Note E – Borrowings and Credit Arrangements and Note I – Commitments and Contingencies for more information.
ASC Topic 820, Fair Value Measurements and Disclosures	FASB ASC Topic 815 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by FASB ASC Topic 820, Fair Value Measurements and Disclosures , by considering the estimated amount we would receive or pay to transfer these instruments at the reporting date and by taking into account current interest rates, foreign currency exchange rates, the creditworthiness of the counterparty for the assets and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. In doing so, we use inputs that include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, other observable inputs for the asset or liability, and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of June 30, 2017 , we have classified all of our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by FASB ASC Topic 820 , as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.
ASC Topic 815, Derivatives and Hedging	We address market risk from changes in foreign currency exchange rates and interest rates through a risk management program that includes the use of derivative financial instruments and we operate the program pursuant to documented corporate risk management policies. Our derivative instruments do not subject our earnings or cash flows to material risk, as gains and losses on these derivatives generally offset losses and gains on the item being hedged. We do not enter into derivative transactions for speculative purposes and we do not have any non-derivative instruments that are designated as hedging instruments pursuant to FASB ASC Topic 815 , Derivatives and Hedging .
ASC Topic 712, Compensation - Non-retirement Postemployment Benefits and ASC Topic 420, Exit or Disposal Cost Obligations	Termination benefits represent amounts incurred pursuant to our ongoing benefit arrangements and amounts for “one-time” involuntary termination benefits and have been recorded in accordance with FASB ASC Topic 712 , Compensation - Nonretirement and Postemployment Benefits and FASB ASC Topic 420 , Exit or Disposal Cost Obligations . Other restructuring costs, which represent primarily consulting fees and costs related to contract cancellations, are being recorded as incurred in accordance with FASB ASC Topic 420 . Accelerated depreciation is being recorded over the adjusted remaining useful life of the related assets and program management and production line transfer costs are being recorded as incurred.	2
Legal Costs, Policy [Policy Text Block]	In accordance with FASB ASC Topic 450, Contingencies , we accrue anticipated costs of settlements, damages and losses for product liability claims and, under certain conditions, costs of defense, based on historical experience or to the extent specific losses are probable and estimable. Otherwise, we expense these costs as incurred. If the estimate of a probable loss is a range and no amount within the range is more likely, we accrue the minimum amount of the range.
ASC Update No. 2014-09, Revenue from Contracts with Customers (Topic 606) [Policy Text Block]	ASC Update No. 2014-09 In May 2014, the FASB issued ASC Update No. 2014-09, Revenue from Contracts with Customers (Topic 606), which has been subsequently updated. The purpose of Update No. 2014-09 is to provide enhancements to the quality and consistency of how revenue is reported while also improving comparability in the financial statements of companies using U.S. GAAP and International Financial Reporting Standards. The core principle requires entities to recognize revenue in a manner that depicts the transfer of goods or services to customers in amounts that reflect the consideration an entity expects to be entitled to in exchange for those goods or services. FASB ASC Topic 606 , as amended, becomes effective for annual periods beginning after December 15, 2017, at which point we plan to adopt the standard. We currently plan to adopt the standard using the “modified retrospective method.” Under that method, we will apply the rules to contracts that are not completed as of January 1, 2018, and recognize the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings. We have reached conclusions on our key accounting assessments related to the standard and are finalizing our accounting policies. Based on our initial assessment, we believe the timing of revenue recognition for our primary revenue stream, single-use medical device sales, will not materially change. We are still finalizing our accounting policies related to variable consideration and assessing disclosure requirements. Upon adopting FASB ASC Topic 606 , we will provide additional disclosures in the notes to the consolidated financial statements, specifically related to disaggregated revenue, contract balances and performance obligations. In 2017, we are implementing new internal controls as part of our efforts to adopt the new revenue recognition standard. These internal controls include providing global training to our finance team and holding regular meetings with management and the Audit Committee to review and approve key decisions. Upon adoption, we expect to implement new internal controls related to our accounting policies and procedures. We will require new internal controls to address risks associated with applying the five-step model, specifically related to judgments made in connection to variable consideration and applying the constraint. Additionally, we will establish monitoring controls to identify new sales arrangements and changes in our business environment that could impact our current accounting assessment. During the second half of 2017, we expect to finalize our impact assessment and redesign impacted processes, policies and controls.
ASC Update No. 2016-01, Financial Instruments [Policy Text Block]	ASC Update No. 2016-01 In January 2016, the FASB issued ASC Update No. 2016-01, Financial Instruments - Overall (Subtopic 825-10) : Recognition and Measurement of Financial Assets and Financial Liabilities. The purpose of Update No. 2016-01 is to improve financial reporting for financial instruments by reducing the number of items recorded to other comprehensive income. It requires entities to measure equity investments that do not result in consolidation and are not accounted for under the equity method at fair value with changes recognized in net income. However, an entity may choose to measure equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. It simplifies the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment to identify impairment. It also requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset and liability. Update No. 2016-01 is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. Early application of certain provisions is permitted. We are unable to determine the effect that the adoption will have on our financial position and results of operations, as it will depend on the equity investments at the adoption date and their future performance.
ASC Update No. 2016-02, Leases (Topic 842) [Policy Text Block]	ASC Update No. 2016-02 In February 2016, the FASB issued ASC Update No. 2016-02, Leases (Topic 842) . The purpose of Update No. 2016-02 is to increase the transparency and comparability among organizations by recognizing lease asset and lease liabilities on the balance sheet, including those previously classified as operating leases under current U.S. GAAP and disclosing key information about leasing arrangements. Update No. 2016-02 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual. Early application is permitted. We are in the process of determining the effect that the adoption will have on our financial position and results of operations.
ASC Update No. 2016-09, Compensation- Stock Compensation (Topic 718) [Policy Text Block]	ASC Update No. 2016-09 In March 2016, the FASB issued ASC Update No. 2016-09, Compensation - Stock Compensation (Topic 718) : Improvements to Employee Share-Based Payment Accounting . The purpose of Update No. 2016-09 is to simplify accounting for share-based payment transactions, such as, the accounting for income taxes, statutory tax withholding requirements, forfeitures and statement of cash flow presentation. Update No. 2016-09 was effective for annual periods beginning after December 15, 2016, including interim periods within those annual periods. We adopted Update No. 2016-09 prospectively in the first quarter of 2017 and, as such, no prior periods were adjusted. We previously recorded income tax benefits or deficiencies to additional paid-in capital; however, Update No. 2016-09 requires that all tax benefits or deficiencies be recorded to the provision for income taxes. In the first quarter of 2017, we recorded an income tax benefit of $28 million , which we expect represents the majority of excess tax benefits in 2017 due to the annual vesting of our awards during the first quarter. The actual impact to future periods will depend on the price of our stock, number of stock options exercised and other factors that are difficult to predict. In the first quarter of 2017, a cumulative effect adjustment of $76 million was recorded to retained earnings upon adoption for windfall tax benefits not previously recognized.
ASC Update No. 2017-10, Service Concession Arrangements (Topic 853): Determining the Customer of the Operation Services (a consensus of the FASB Emerging Issues Task Force) [Policy Text Block]	ASC Update No. 2017-10 In May 2017, the FASB issued ASC Update No. 2017-10, Service Concession Arrangements (Topic 853) : Determining the Customer of the Operation Services (a consensus of the FASB Emerging Issues Task Force) . The purpose of Update No. 2017-10 is to address the diversity in practice as to how an operating entity determines the customer of the operation services in a service concession agreement. Update No. 2017-10 is effective the same time as FASB ASC Topic 606 and requires the same transition method elected for FASB ASC Topic 606 . The adoption of Update No. 2017-10 is not expected to have a material impact on our financial position or results of operations.
ASC Update No. 2016-13 [Policy Text Block]	ASC Update No. 2016-13 In June 2016, the FASB issued ASC Update No. 2016-13, Financial Instruments - Credit Losses (Topic 326) : Measurement of Credit Losses on Financial Instruments . The purpose of Update No. 2016-13 is to replace the current incurred loss impairment methodology for financial assets measured at amortized cost with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information, including forecasted information, to develop credit loss estimates. Update No. 2016-13 is effective for annual periods beginning after December 15, 2019, including interim periods within those annual periods. Early application is permitted for annual periods beginning after December 15, 2018. We are in the process of determining the effect that the adoption will have on our financial position and results of operations.
ASC Update No. 2016-15, Statement of Cash Flows [Policy Text Block]	ASC Update No. 2016-15 In August 2016, the FASB issued ASC Update No. 2016-15, Statement of Cash Flows (Topic 230) : Classification of Certain Cash Receipts and Cash Payments. The purpose of Update No. 2016-15 is to reduce the diversity in practice in presentation and classification of the following items within the statement of cash flows: debt prepayments, or debt extinguishment costs, settlement of zero coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, proceeds from the settlement of corporate-owned life insurance policies, distributions received from equity method investments and beneficial interests in securitization transactions. It also addresses classification of transactions that have characteristics of more than one class of cash flows. Update No. 2016-15 is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. Early adoption is permitted, including application in an interim period. We are in the process of determining the effect that the adoption will have on our consolidated statements of cash flows.
ASU Update No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory [Policy Text Block]	ASC Update No. 2016-16 In October 2016, the FASB issued ASC Update No. 2016-16, Income Taxes (Topic 740) : Intra-Entity Transfers of Assets Other Than Inventory . The purpose of Update No. 2016-16 is to allow an entity to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs, as opposed to waiting until the asset is sold to a third party, or impaired. Update No. 2016-16 is effective for annual periods beginning after December 15, 2017, including interim periods within those annual periods. Early application is permitted as of the beginning of an annual period for which financial statements have not been issued or made available for issuance. We are in the process of determining the effect that the adoption will have on our financial position and results of operations.
ASU Update No. 2016-17, Consolidation (Topic 810): Interests Held through Related Parties That Are under Common Control [Policy Text Block]	ASC Update No. 2016-17 In October 2016, the FASB issued ASC Update No. 2016-17, Consolidation (Topic 810) : Interests Held through Related Parties That Are under Common Control . The purpose of Update No. 2016-17 is to amend the consolidation guidance from Update No. 2015-02 on how a reporting entity that is the single decision maker of a variable interest entity (VIE) should treat indirect interests in the entity held through related parties that are under common control with the reporting entity when determining whether it is the primary beneficiary of that VIE. The amendment requires that a single decision maker include those indirect interests held through related parties that are under common control with the single decision maker on a proportionate basis consistent with indirect interests held through other related parties. Update No. 2016-17 was effective for annual periods beginning after December 15, 2016, including interim periods within those annual periods. We adopted Update No. 2016-17 in the first quarter of 2017. The adoption of Update No. 2016-17 did not have a material impact on our financial position or results of operations.
ASC Update No. 2016-19, Technical Corrections and Improvements [Policy Text Block]	ASC Update No. 2016-19 In December 2016, the FASB issued ASC Update No. 2016-19, Technical Corrections and Improvements. The purpose of Update No. 2016-19 is to clarify or correct unintended applications of guidance that affects a wide variety of topics in the ASC. Most of the amendments in this Update did not require transition guidance and were effective immediately. Six amendments in this update clarified guidance or corrected references in the ASC and were effective for annual periods beginning after December 15, 2016, including interim periods within these annual periods. We adopted these amendments in the first quarter of 2017. The adoption of Update No. 2016-19 did not have a material impact on our financial position or results of operations.
ASC Update No. 2017-04, Intangibles - Goodwill and Other Topics (Topic 350): Simplifying the Test for Goodwill Impairment [Policy Text Block]	ASC Update No. 2017-04 In January 2017, the FASB issued ASC Update No. 2017-04, Intangibles - Goodwill and Other Topics (Topic 350) : Simplifying the Test for Goodwill Impairment . The purpose of Update No. 2017-04 is to reduce the cost and complexity of evaluating goodwill for impairment. It eliminates the need for entities to calculate the impaired fair value of goodwill by assigning the fair value of a reporting unit to all of its assets and liabilities as if that reporting unit had been acquired in a business combination. Under this amendment, an entity will perform its goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An impairment charge is recognized for the amount by which the carrying value exceeds the reporting unit's fair value. We elected to early adopt Update No. 2017-04 prospectively in the first quarter of 2017. The adoption of Update No. 2017-04 did not have a material impact on our financial position or results of operations.

Acquisitions and Strategic In25

Acquisitions and Strategic Investments (Tables)	6 Months Ended
	Jun. 30, 2017
Business Acquisition [Line Items]
Business Combination, Components of Purchase Price [Table Text Block]	The components of the aggregate preliminary purchase price are as follows (in millions): Net cash paid for acquisition $ 392
Investment [Table Text Block]	The aggregate carrying amount of our strategic investments as of June 30, 2017 and December 31, 2016 were comprised of the following categories: As of (in millions) June 30, 2017 December 31, 2016 Equity method investments $ 208 $ 265 Cost method investments 42 20 Available-for-sale securities 30 20 Notes receivable 44 42 $ 324 $ 347
Business Combination, Purchase Price Allocation Schedule [Table Text Block]	The following summarizes the preliminary purchase price allocation for the Symetis acquisition as of June 30, 2017 (in millions): Goodwill $ 185 Amortizable intangible assets 278 Other assets acquired 25 Liabilities assumed (96 ) $ 392
Business Acquisition, Purchase Price Allocation, Intangible Assets, Description [Table Text Block]	We allocated a portion of the purchase price to specific intangible asset categories as follows: Amount Assigned (in millions) Amortization Period (in years) Range of Risk- Adjusted Discount Rates used in Purchase Price Allocation Amortizable intangible assets: Technology-related $ 268 13 23.5% Other intangible assets 10 2-13 23.5% $ 278
Rollforward of Fair Value of Contingent Consideration [Table Text Block]	Changes in the fair value of our contingent consideration liabilities were as follows (in millions): Balance as of December 31, 2016 $ 204 Fair value adjustments (74 ) Contingent payments related to prior period acquisitions (28 ) Balance as of June 30, 2017 $ 102
Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block]	The recurring Level 3 fair value measurements of our contingent consideration liabilities include the following significant unobservable inputs: Contingent Consideration Liabilities Fair Value as of June 30, 2017 Valuation Technique Unobservable Input Range R&D and Commercialization-based Milestones $44 million Discounted Cash Flow Discount Rate 2% - 3% Projected Year of Payment 2017 - 2021 Revenue-based Payments $58 million Discounted Cash Flow Discount Rate 11% - 15% Projected Year of Payment 2017 - 2026

Goodwill and Other Intangible26

Goodwill and Other Intangible Assets Goodwill (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Description of unobservable inputs used in Level 3 fair value measurements [Table Text Block]	The recurring Level 3 fair value measurements of our contingent consideration liabilities include the following significant unobservable inputs: Contingent Consideration Liabilities Fair Value as of June 30, 2017 Valuation Technique Unobservable Input Range R&D and Commercialization-based Milestones $44 million Discounted Cash Flow Discount Rate 2% - 3% Projected Year of Payment 2017 - 2021 Revenue-based Payments $58 million Discounted Cash Flow Discount Rate 11% - 15% Projected Year of Payment 2017 - 2026
Schedule of Goodwill [Table Text Block]	The following represents our goodwill balance by global reportable segment: (in millions) Cardiovascular Rhythm Management MedSurg Total Balance as of December 31, 2016 $ 3,513 $ 290 $ 2,875 $ 6,678 Impact of foreign currency fluctuations and other changes in carrying amount 4 1 3 8 Goodwill acquired 185 — — 185 Balance as of June 30, 2017 $ 3,702 $ 291 $ 2,878 $ 6,871 The gross carrying amount of goodwill and other intangible assets and the related accumulated amortization for intangible assets subject to amortization and accumulated write-offs of goodwill as of June 30, 2017 and December 31, 2016 are as follows: As of June 30, 2017 December 31, 2016 Gross Carrying Accumulated Gross Accumulated (in millions) Amount Write-offs Amount Write-offs Amortizable intangible assets Technology-related $ 9,390 $ (4,675 ) $ 9,123 $ (4,468 ) Patents 511 (370 ) 529 (374 ) Other intangible assets 1,632 (779 ) 1,583 (722 ) $ 11,533 $ (5,824 ) $ 11,235 $ (5,564 ) Unamortizable intangible assets Goodwill $ 16,771 $ (9,900 ) $ 16,578 $ (9,900 ) In-process research and development (IPR&D) 92 — 92 — Technology-related 120 — 120 — $ 16,983 $ (9,900 ) $ 16,790 $ (9,900 ) The following is a rollforward of accumulated goodwill write-offs by global reportable segment: (in millions) Cardiovascular Rhythm Management MedSurg Total Accumulated write-offs as of December 31, 2016 $ (1,479 ) $ (6,960 ) $ (1,461 ) $ (9,900 ) Goodwill written off — — — — Accumulated write-offs as of June 30, 2017 $ (1,479 ) $ (6,960 ) $ (1,461 ) $ (9,900 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Gains (losses) recognized in earnings for derivatives designed as hedging instruments	The following presents the effect of our derivative instruments designated as cash flow hedges under FASB ASC Topic 815 on our accompanying unaudited condensed consolidated statements of operations during the second quarter and the first half of 2017 and 2016 : (in millions) Amount of Pre-tax Gain (Loss) Recognized in OCI (Effective Portion) Amount of Pre-tax Gain (Loss) Reclassified from AOCI into Earnings (Effective Portion) Location in Statement of Operations Three Months Ended June 30, 2017 Currency hedge contracts $ (6 ) $ 27 Cost of products sold $ (6 ) $ 27 Three Months Ended June 30, 2016 Currency hedge contracts $ (99 ) $ 32 Cost of products sold $ (99 ) $ 32 Six Months Ended June 30, 2017 Currency hedge contracts $ (64 ) $ 55 Cost of products sold Interest rate derivative contracts — 1 Interest Expense $ (64 ) $ 56 Six Months Ended June 30, 2016 Currency hedge contracts $ (158 ) $ 80 Cost of products sold $ (158 ) $ 80
Net foreign currency gain (loss) [Table Text Block]	Net gains and losses on currency hedge contracts not designated as hedging instruments were offset by net losses and gains from foreign currency transaction exposures, as shown in the following table: (in millions) Location in Statement of Operations Three Months Ended Six Months Ended June 30, June 30, 2017 2016 2017 2016 Net gain (loss) on currency hedge contracts Other, net $ 5 $ (28 ) $ (12 ) $ (67 ) Net gain (loss) on foreign currency transaction exposures Other, net (13 ) 29 4 63 Net foreign currency gain (loss) Other, net $ (8 ) $ 1 $ (8 ) $ (4 )
Classification of derivative assets and liabilities within level 2	The following are the balances of our derivative assets and liabilities as of June 30, 2017 and December 31, 2016 : As of June 30, December 31, (in millions) Location in Balance Sheet (1) 2017 2016 Derivative Assets: Currently or Previously Designated Hedging Instruments Currency hedge contracts Other current assets $ 20 $ 98 Currency hedge contracts Other long-term assets 52 65 72 163 Non-Designated Hedging Instruments Currency hedge contracts Other current assets 24 36 Total Derivative Assets $ 96 $ 199 Derivative Liabilities: Currently or Previously Designated Hedging Instruments Currency hedge contracts Other current liabilities $ 25 $ 3 Currency hedge contracts Other long-term liabilities 11 4 36 7 Non-Designated Hedging Instruments Currency hedge contracts Other current liabilities 34 19 Total Derivative Liabilities $ 70 $ 26 (1) We classify derivative assets and liabilities as current when the remaining term of the derivative contract is one year or less.
Assets and liabilities measured at fair value on a recurring basis	Assets and liabilities measured at fair value on a recurring basis consist of the following as of June 30, 2017 and December 31, 2016 : As of June 30, 2017 December 31, 2016 (in millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Money market and government funds $ 66 $ — $ — $ 66 $ 42 $ — $ — $ 42 Available-for-sale securities 30 — — 30 20 — — 20 Currency hedge contracts — 96 — 96 — 199 — 199 $ 96 $ 96 $ — $ 192 $ 62 $ 199 $ — $ 261 Liabilities Currency hedge contracts $ — $ 70 $ — $ 70 $ — $ 26 $ — $ 26 Accrued contingent consideration — — 102 102 — — 204 204 $ — $ 70 $ 102 $ 172 $ — $ 26 $ 204 $ 230

Borrowings and Credit Arrange28

Borrowings and Credit Arrangements (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Schedule of debt maturities	The debt maturity schedule for the significant components of our long-term debt obligations as of June 30, 2017 and December 31, 2016 is as follows: in millions, except interest rates Maturity Date June 30, 2017 December 31, 2016 January 2017 5.125% Notes January 2017 $ — $ 250 October 2018 2.650% Notes October 2018 600 600 January 2020 6.000% Notes January 2020 850 850 May 2020 2.850% Notes May 2020 600 600 May 2022 3.375% Notes May 2022 500 500 May 2025 3.850% Notes May 2025 750 750 October 2023 4.125% Notes October 2023 450 450 November 2035 6.250% Notes November 2035 350 350 January 2040 7.375% Notes January 2040 300 300 August 2018 Term Loan August 2018 — 150 August 2020 Term Loan 2018-2020 400 600 Debt discount 2018-2040 (7 ) (8 ) Deferred financing costs 2018-2040 (22 ) (24 ) Interest rate swaps 2020-2023 45 51 Capital lease obligation 2018-2020 1 1 Long-term debt $ 4,817 $ 5,420 Note: The table above does not include unamortized amounts related to interest rate contracts designated as cash flow hedges.

Restructuring Related Activit29

Restructuring Related Activities (Tables)	6 Months Ended
	Jun. 30, 2017
Restructuring and Related Cost [Line Items]
Restructuring and related costs	The following presents these costs (credits) by major type and line item within our accompanying unaudited condensed consolidated statements of operations: Three Months Ended June 30, 2017 (in millions) Termination Benefits Accelerated Depreciation Transfer Costs Other Total Restructuring charges $ — $ — $ — $ 1 $ 1 Restructuring-related expenses: Cost of products sold — — 12 — 12 Selling, general and administrative expenses — 2 — 1 3 — 2 12 1 15 $ — $ 2 $ 12 $ 2 $ 16 All charges incurred in the second quarter of 2017 were related to the 2016 Restructuring Plan. Three Months Ended June 30, 2016 (in millions) Termination Benefits Accelerated Depreciation Transfer Costs Other Total Restructuring charges $ 14 $ — $ — $ — $ 14 Restructuring-related expenses: Cost of products sold — — 7 — 7 Selling, general and administrative expenses — 3 — 2 5 — 3 7 2 12 $ 14 $ 3 $ 7 $ 2 $ 26 (in millions) Termination Benefits Accelerated Depreciation Transfer Costs Other Total 2016 Restructuring Plan $ 18 $ — $ 1 $ — $ 19 2014 Restructuring Plan (4 ) 3 6 2 7 $ 14 $ 3 $ 7 $ 2 $ 26 Six Months Ended June 30, 2017 (in millions) Termination Benefits Accelerated Depreciation Transfer Costs Other Total Restructuring charges $ 3 $ — $ — $ 2 $ 5 Restructuring-related expenses: Cost of products sold — — 24 — 24 Selling, general and administrative expenses — 3 — 3 6 — 3 24 3 30 $ 3 $ 3 $ 24 $ 5 $ 35 All charges incurred in the first half of 2017 were related to the 2016 Restructuring Plan. Six Months Ended June 30, 2016 (in millions) Termination Accelerated Transfer Other Total Restructuring charges $ 15 $ — $ — $ 2 $ 17 Restructuring-related expenses: Cost of products sold — — 12 — 12 Selling, general and administrative expenses — 4 — 6 10 — 4 12 6 22 $ 15 $ 4 $ 12 $ 8 $ 39 (in millions) Termination Accelerated Transfer Other Total 2016 Restructuring Plan $ 18 $ — $ 1 $ — $ 19 2014 Restructuring Plan (3 ) 4 11 8 20 $ 15 $ 4 $ 12 $ 8 $ 39
Cumulative restructuring charges	(in millions) 2016 Restructuring Plan Termination benefits $ 27 Other 6 Total restructuring charges 33 Accelerated depreciation 5 Transfer costs 39 Other 5 Restructuring-related expenses 49 $ 82
Cash payments associated with restructuring initiatives	These payments were made using cash generated from operations and are comprised of the following: (in millions) 2016 Restructuring Plan Six Months Ended June 30, 2017 Termination benefits $ 6 Transfer costs 24 Other 3 $ 33 Program to Date Termination benefits $ 14 Transfer costs 39 Other 7 $ 60
Summary of accrued expenses within accompanying unaudited condensed consolidated balance sheets	The following is a rollforward of the termination benefit liability associated with our 2016 Restructuring Plan, which is reported as a component of accrued expenses included in our accompanying unaudited condensed balance sheets: (in millions) 2016 Restructuring Plan Accrued as of December 31, 2016 $ 16 Charges (credits) 3 Cash payments (6 ) Accrued as of June 30, 2017 $ 13
2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring and related costs	The following table provides a summary of our estimates of costs associated with the 2016 Restructuring Plan through the end of 2018 by major type of cost: Type of cost Total estimated amount expected to be incurred Restructuring charges: Termination benefits $60 million to $70 million Other (1) $10 million to $20 million Restructuring-related expenses: Other (2) $105 million to $135 million $175 million to $225 million (1) Consists primarily of consulting fees and costs associated with contract cancellations. (2) Comprised of other costs directly related to the 2016 Restructuring Plan, including program management, accelerated depreciation and costs to transfer product lines among facilities.

Supplemental Balance Sheet In30

Supplemental Balance Sheet Information (Tables)	6 Months Ended
	Jun. 30, 2017
Supplemental Balance Sheet Information [Abstract]
Trade accounts receivable, net	As of (in millions) June 30, 2017 December 31, 2016 Accounts receivable $ 1,564 $ 1,591 Less: allowance for doubtful accounts (74 ) (73 ) Less: allowance for sales returns (46 ) (46 ) $ 1,444 $ 1,472
Rollforward of allowances for doubtful accounts	Three Months Ended Six Months Ended (in millions) 2017 2016 2017 2016 Beginning balance $ 75 $ 80 $ 73 $ 75 Net charges to expenses 2 3 5 7 Utilization of allowances (3 ) (3 ) (4 ) (2 ) Ending balance $ 74 $ 80 $ 74 $ 80
Inventory Disclosure [Text Block]	As of (in millions) June 30, 2017 December 31, 2016 Finished goods $ 652 $ 625 Work-in-process 97 94 Raw materials 274 236 $ 1,023 $ 955
Other Current Assets [Text Block]	As of (in millions) June 30, 2017 December 31, 2016 Prepaid expenses $ 91 $ 58 Restricted cash 251 243 Other 143 240 $ 485 $ 541
Property, plant and equipment, net	As of (in millions) June 30, 2017 December 31, 2016 Land $ 92 $ 91 Buildings and improvements 1,043 981 Equipment, furniture and fixtures 3,081 2,955 Capital in progress 305 338 4,521 4,365 Less: accumulated depreciation 2,870 2,735 $ 1,651 $ 1,630
Schedule of Accrued Liabilities	As of (in millions) June 30, 2017 December 31, 2016 Legal reserves $ 1,152 $ 1,062 Payroll and related liabilities 486 572 Accrued contingent consideration 39 63 Other 561 615 $ 2,238 $ 2,312
Other long-term liabilities	As of (in millions) June 30, 2017 December 31, 2016 Accrued income taxes $ 797 $ 781 Legal reserves 627 961 Accrued contingent consideration 63 141 Other long-term liabilities 485 455 $ 1,972 $ 2,338
Accrued warranties	Six Months Ended (in millions) 2017 2016 Beginning Balance $ 22 $ 23 Provision 13 10 Settlements/reversals (13 ) (13 ) Ending Balance $ 22 $ 20

Weighted Average Shares Outst31

Weighted Average Shares Outstanding (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares [Table Text Block]	Three Months Ended Six Months Ended (in millions) 2017 2016 2017 2016 Weighted average shares outstanding - basic 1,369.8 1,357.4 1,367.6 1,353.9 Net effect of common stock equivalents 21.3 — * 23.0 — * Weighted average shares outstanding - assuming dilution 1,391.1 1,357.4 1,390.6 1,353.9

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Segment Reporting Information By Segment	A reconciliation of the totals reported for the reportable segments to the applicable line items in our accompanying unaudited condensed consolidated statements of operations is as follows: Three Months Ended Six Months Ended (in millions) 2017 2016 2017 2016 (restated) (restated) Net sales Interventional Cardiology $ 612 $ 580 $ 1,217 $ 1,140 Peripheral Interventions 277 260 545 508 Cardiovascular 889 840 1,762 1,648 Cardiac Rhythm Management 484 476 956 915 Electrophysiology 67 60 133 120 Rhythm Management 551 536 1,089 1,035 Endoscopy 405 361 792 700 Urology and Pelvic Health 282 255 546 485 Neuromodulation 154 135 296 257 MedSurg 841 751 1,634 1,442 Net sales allocated to reportable segments 2,281 2,127 4,485 4,125 Impact of foreign currency fluctuations (24 ) (1 ) (67 ) (35 ) $ 2,257 $ 2,126 $ 4,418 $ 4,090 Income (loss) before income taxes Cardiovascular $ 268 $ 249 $ 513 $ 503 Rhythm Management 115 73 216 140 MedSurg 270 234 508 448 Operating income allocated to reportable segments 653 556 1,237 1,091 Corporate expenses and currency exchange (66 ) (58 ) (153 ) (99 ) Acquisition-related, restructuring- and restructuring-related, and litigation-related net credits (charges) (220 ) (697 ) (210 ) (762 ) Amortization expense (142 ) (135 ) (285 ) (271 ) Operating income (loss) 225 (334 ) 589 (41 ) Other expense, net (134 ) (63 ) (193 ) (128 ) Income (loss) before income taxes $ 91 $ (397 ) $ 396 $ (169 )

Changes in Other Comprehensiv33

Changes in Other Comprehensive Income (Tables)	6 Months Ended
	Jun. 30, 2017
Changes in Other Comprehensive Income [Abstract]
Changes in Other Comprehensive Income [Table Text Block]	The following table provides the reclassifications out of other comprehensive income for the three and six months ended June 30, 2017 and June 30, 2016 . Amounts in the chart below are presented net of tax. Three Months Ended June 30, 2017 (in millions) Foreign Currency Translation Adjustments Unrealized Gains/Losses on Derivative Financial Instruments Unrealized Gains/Losses on Available-for-Sale Securities Defined Benefit Pension Items / Other Total Balance as of March 31, 2017 $ (71 ) $ 52 $ (6 ) $ (21 ) $ (46 ) Other comprehensive income (loss) before reclassifications 13 (4 ) — — 9 Amounts reclassified from accumulated other comprehensive income — (17 ) 2 (1 ) (16 ) Net current-period other comprehensive income 13 (21 ) 2 (1 ) (7 ) Balance as of June 30, 2017 $ (58 ) $ 31 $ (4 ) $ (22 ) $ (53 ) Three Months Ended June 30, 2016 (in millions) Foreign Currency Translation Adjustments Unrealized Gains/Losses on Derivative Financial Instruments Defined Benefit Pension Items / Other Total Balance as of March 31, 2016 $ (38 ) $ 83 $ (10 ) $ 35 Other comprehensive income (loss) before reclassifications (21 ) (64 ) (1 ) (86 ) Amounts reclassified from accumulated other comprehensive income — (20 ) 1 (19 ) Net current-period other comprehensive income (21 ) (84 ) — (105 ) Balance as of June 30, 2016 $ (59 ) $ (1 ) $ (10 ) $ (70 ) Six Months Ended June 30, 2017 (in millions) Foreign Currency Translation Adjustments Unrealized Gains/Losses on Derivative Financial Instruments Unrealized Gains/Losses on Available-for-Sale Securities Defined Benefit Pension Items / Other Total Balance as of December 31, 2016 $ (79 ) $ 107 $ (6 ) $ (21 ) $ 1 Other comprehensive income (loss) before reclassifications 21 (41 ) — (2 ) (22 ) Amounts reclassified from accumulated other comprehensive income — (35 ) 2 1 (32 ) Net current-period other comprehensive income 21 (76 ) 2 (1 ) (54 ) Balance as of June 30, 2017 $ (58 ) $ 31 $ (4 ) $ (22 ) $ (53 ) Six Months Ended June 30, 2016 (in millions) Foreign currency translation adjustments Unrealized gains/losses on derivative financial instruments Defined benefit pension items / Other Total Balance as of December 31, 2015 $ (54 ) $ 152 $ (10 ) $ 88 Other comprehensive income (loss) before reclassifications (5 ) (102 ) (3 ) (110 ) Amounts reclassified from accumulated other comprehensive income — (51 ) 3 (48 ) Net current-period other comprehensive income (5 ) (153 ) — (158 ) Balance as of June 30, 2016 $ (59 ) $ (1 ) $ (10 ) $ (70 )

Acquisitions and Strategic In34

Acquisitions and Strategic Investments (Details) - USD ($) $ in Millions	May 16, 2017	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill		$ 6,871		$ 6,871		$ 6,678
Business Combination, Contingent Consideration, Asset		102		102		$ 204
Payments for acquisitions of businesses, net of cash acquired				392	$ 0
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		24	$ (33)	74	(37)
Payment of contingent consideration				28	$ 77
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High		1,278		1,278
revenue-based payments [Member] | Discounted cash flow [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability		58		58
R&D and Commercialization-based Milestone [Member] | Discounted cash flow [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability		$ 44		$ 44
Minimum [Member] | revenue-based payments [Member] | Discounted cash flow [Member]
Business Acquisition [Line Items]
Fair Value Inputs, Discount Rate				11.00%
contingent consideration liability, projected year of payment				2,017
Minimum [Member] | R&D and Commercialization-based Milestone [Member] | Discounted cash flow [Member]
Business Acquisition [Line Items]
Fair Value Inputs, Discount Rate				2.00%
contingent consideration liability, projected year of payment				2,017
Maximum [Member] | revenue-based payments [Member] | Discounted cash flow [Member]
Business Acquisition [Line Items]
Fair Value Inputs, Discount Rate				15.00%
contingent consideration liability, projected year of payment				2,026
Maximum [Member] | R&D and Commercialization-based Milestone [Member] | Discounted cash flow [Member]
Business Acquisition [Line Items]
Fair Value Inputs, Discount Rate				3.00%
contingent consideration liability, projected year of payment				2,021
Customer Relationships [Member]
Business Acquisition [Line Items]
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				13 years
Technology-Based Intangible Assets [Member]
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired				$ 268
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				13 years
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation		23.50%		23.50%
Other Intangible Assets [Member]
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired				$ 10
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life				2 years
Range of Risk Adjusted Discount Rates used in Purchase Price Allocation		23.50%		23.50%
Finite-Lived Intangible Assets [Member]
Business Acquisition [Line Items]
Finite-lived Intangible Assets Acquired				$ 278
2017 Acquisitions [Member]
Business Acquisition [Line Items]
Goodwill		$ 185		185
Payments for acquisitions of businesses, net of cash acquired				392
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles		278		278
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets		25		25
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities		$ (96)		(96)
Business Combination, Consideration Transferred, Including Equity Interest in Acquiree Held Prior to Combination				$ 392
Symetis [Member]
Business Acquisition [Line Items]
Payments for acquisitions of businesses, net of cash acquired	$ 430

Strategic Investments (Details)

Strategic Investments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Schedule of Investments [Line Items]
Other Nonoperating Income (Expense)	$ 76	$ 4	$ 78	$ 10
Equity Method Investments	208		208		$ 265
Cost Method Investments	42		42		20
Available-for-sale Securities	30		30		20
Notes Receivable From Portfolio Companies	44		44		42
Investments	324		$ 324		$ 347
investment impairment [Member]
Schedule of Investments [Line Items]
Other Nonoperating Income (Expense)	$ 53

Goodwill and Other Intangible36

Goodwill and Other Intangible Assets (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Goodwill [Line Items]
Finite-Lived Intangible Assets, Gross	$ 11,533	$ 11,235
Finite-Lived Intangible Assets, Accumulated Amortization	(5,824)	(5,564)
Indefinite-lived intangible assets, including goodwill	16,983	16,790
Indefinite-lived intangible assets, accumulated write-offs	(9,900)	(9,900)
Goodwill	6,871	6,678
Goodwill, Purchase Accounting Adjustments	8
Goodwill, Acquired During Period	185
Goodwill, Impaired, Accumulated Impairment Loss	(9,900)	(9,900)
Goodwill (Textuals) [Abstract]
Goodwill impairment charge	0
Cardiovascular [Member]
Goodwill [Line Items]
Goodwill	3,702	3,513
Goodwill, Purchase Accounting Adjustments	4
Goodwill, Acquired During Period	185
Goodwill, Impaired, Accumulated Impairment Loss	(1,479)	(1,479)
Goodwill (Textuals) [Abstract]
Goodwill impairment charge	0
Rhythm Management [Member]
Goodwill [Line Items]
Goodwill	291	290
Goodwill, Purchase Accounting Adjustments	1
Goodwill, Acquired During Period	0
Goodwill, Impaired, Accumulated Impairment Loss	(6,960)	(6,960)
Goodwill (Textuals) [Abstract]
Goodwill impairment charge	0
MedSurg [Member]
Goodwill [Line Items]
Goodwill	2,878	2,875
Goodwill, Purchase Accounting Adjustments	3
Goodwill, Acquired During Period	0
Goodwill, Impaired, Accumulated Impairment Loss	(1,461)	(1,461)
Goodwill (Textuals) [Abstract]
Goodwill impairment charge	0
Unclassified Indefinite-lived Intangible Assets [Member]
Goodwill [Line Items]
Goodwill, Gross	16,771	16,578
Goodwill, Impaired, Accumulated Impairment Loss	(9,900)	(9,900)
Technology-related [Member]
Goodwill [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	120	120
In-process research and development [Member]
Goodwill [Line Items]
Indefinite-Lived Intangible Assets (Excluding Goodwill)	92	92
Technology-related [Member]
Goodwill [Line Items]
Finite-Lived Intangible Assets, Gross	9,390	9,123
Finite-Lived Intangible Assets, Accumulated Amortization	(4,675)	(4,468)
Patents [Member]
Goodwill [Line Items]
Finite-Lived Intangible Assets, Gross	511	529
Finite-Lived Intangible Assets, Accumulated Amortization	(370)	(374)
Other Intangible Assets [Member]
Goodwill [Line Items]
Finite-Lived Intangible Assets, Gross	1,632	1,583
Finite-Lived Intangible Assets, Accumulated Amortization	$ (779)	$ (722)

Fair Value Measurements Fair 37

Fair Value Measurements Fair Value Measurements (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Derivative, Notional Amount	$ 2,915		$ 2,915		$ 2,271
Foreign Currency Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net	27	$ 32	55	$ 80
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax, Ending Balance	25		25		102
Foreign Currency Derivative Instruments Not Designated as Hedging Instruments at Fair Value, Net	2,197		2,197		1,830
Unamortized gains on senior notes	45		45		51
Unrealized gain on interest rate cash flow hedges, pretax, AOCI	8		8		9
reduction of interest expense, related to amortization of previously terminated interest rate contracts	3	3	6	6
Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net	14		14
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net			0
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net			1
Derivative Assets	96		96		199
Derivative Liabilities	70		70		26
Available-for-sale Securities	30		30		20
Time Deposits, at Carrying Value					19
Cash	129		129		135
Cost-method Investments, Aggregate Carrying Amount	42		42		20
Debt Instrument, Fair Value Disclosure	6,174		6,174		5,739
Fair Value, Measurements, Recurring [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Money Market Funds, at Carrying Value	66		66		42
Available-for-sale Securities	30		30		20
Foreign Currency Contract, Asset, Fair Value Disclosure	96		96		199
Assets, Fair Value Disclosure	192		192		261
Foreign Currency Contracts, Liability, Fair Value Disclosure	70		70		26
Accrued Contingent Consideration	102		102		204
Liabilities, Fair Value Disclosure	172		172		230
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Money Market Funds, at Carrying Value	66		66		42
Available-for-sale Securities	30		30		20
Assets, Fair Value Disclosure	96		96		62
Foreign Currency Contracts, Liability, Fair Value Disclosure	0		0		0
Accrued Contingent Consideration	0		0		0
Liabilities, Fair Value Disclosure	0		0		0
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Money Market Funds, at Carrying Value	0		0		0
Available-for-sale Securities	0		0		0
Foreign Currency Contract, Asset, Fair Value Disclosure	96		96		199
Assets, Fair Value Disclosure	96		96		199
Foreign Currency Contracts, Liability, Fair Value Disclosure	70		70		26
Accrued Contingent Consideration	0		0		0
Liabilities, Fair Value Disclosure	70		70		26
Fair Value, Measurements, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Money Market Funds, at Carrying Value	0		0		0
Available-for-sale Securities	0		0		0
Assets, Fair Value Disclosure	0		0		0
Foreign Currency Contracts, Liability, Fair Value Disclosure	0		0		0
Accrued Contingent Consideration	102		102		204
Liabilities, Fair Value Disclosure	102		102		204
Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments in Hedges, Assets, at Fair Value	72		72		163
Derivative Instruments in Hedges, Liabilities, at Fair Value	36		36		7
Designated as Hedging Instrument [Member] | Prepaid And Other Current Assets [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments in Hedges, Assets, at Fair Value	20		20		98
Designated as Hedging Instrument [Member] | Other Long Term Assets [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments in Hedges, Assets, at Fair Value	52		52		65
Designated as Hedging Instrument [Member] | Other current liabilities [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments in Hedges, Liabilities, at Fair Value	25		25		3
Designated as Hedging Instrument [Member] | Other Noncurrent Liabilities [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments in Hedges, Liabilities, at Fair Value	11		11		4
Not Designated as Hedging Instrument [Member] | Prepaid And Other Current Assets [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Asset, at Fair Value	24		24		36
Not Designated as Hedging Instrument [Member] | Other current liabilities [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value	34		34		$ 19
Not Designated as Hedging Instrument [Member] | Other, net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	5	(28)	(12)	(67)
Net gain (loss) from foreign currency transaction exposures	(13)	29	4	63
Foreign Currency Transaction Gain (Loss), Realized	(8)	1	(8)	(4)
Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	(6)	(99)	(64)	(158)
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	27	32	56	80
Foreign Exchange Contract [Member] | Cash Flow Hedging [Member] | Designated as Hedging Instrument [Member] | Cost of Sales [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments, Gain (Loss) Recognized in Other Comprehensive Income (Loss), Effective Portion, Net	(6)	(99)	(64)	(158)
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net	$ 27	$ 32	$ 55	$ 80

Borrowings and Credit Arrange38

Borrowings and Credit Arrangements (Details) $ in Millions, ¥ in Billions	3 Months Ended		6 Months Ended	12 Months Ended
	Sep. 30, 2017USD ($)	Mar. 31, 2017USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Jun. 30, 2017JPY (¥)	Apr. 18, 2012USD ($)
Debt Instrument [Line Items]
Total debt			$ 5,835	$ 5,484
Line of Credit Facility, Maximum Borrowing Capacity		$ 400		300
Line of Credit Facility, Fair Value of Amount Outstanding			0	$ 60
Maximum amount of proceeds from sale of finance receivables			$ 434
Average interest rate of de-recognized receivables			1.80%	1.80%
De-recognized receivables			$ 165	$ 152
Long-term Debt			$ (4,817)	(5,420)
January 2017 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			5.125%		5.125%
Long-term Debt			$ 0	(250)
October 2018 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			2.65%		2.65%
Long-term Debt			$ (600)	(600)
January 2020 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			6.00%		6.00%
Long-term Debt			$ (850)	(850)
May 2020 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			2.85%		2.85%
Long-term Debt			$ (600)	(600)
May 2022 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.375%		3.375%
Long-term Debt			$ (500)	(500)
May 2025 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			3.85%		3.85%
Long-term Debt			$ (750)	(750)
October 2023 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			4.125%		4.125%
Long-term Debt			$ (450)	(450)
November 2035 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			6.25%		6.25%
Long-term Debt			$ (350)	(350)
January 2040 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage			7.375%		7.375%
Long-term Debt			$ (300)	(300)
2013 Term Loan [Member]
Debt Instrument [Line Items]
Long-term Debt			0	(150)
2015 Term Loan [Member]
Debt Instrument [Line Items]
Long-term Debt			(400)	(600)
Senior Notes [Member]
Debt Instrument [Line Items]
Long-term Debt			(4,400)	(4,650)
Unsecured Term Loan Facility [Member]
Debt Instrument [Line Items]
Long-term Debt			(400)	(750)
Premiums, accelerated amortization of debt issuance costs & investor discount costs [Member]
Debt Instrument [Line Items]
Long-term Debt			(7)	(8)
Securities Financing Transaction, Cost [Member]
Debt Instrument [Line Items]
Long-term Debt			(22)	(24)
Interest Rate Swap [Member]
Debt Instrument [Line Items]
Long-term Debt			(45)	(51)
Capital Lease Obligations [Member]
Debt Instrument [Line Items]
Long-term Debt			(1)	(1)
Line of Credit [Member]
Debt Instrument [Line Items]
Commercial Paper			2,000
Senior Notes [Member]
Debt Instrument [Line Items]
Extinguishment of Debt, Amount		$ 250
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Debt Instrument [Line Items]
Commercial Paper			$ 1,013
Commercial Paper [Member]
Debt Instrument [Line Items]
Short-term Debt, Weighted Average Interest Rate			1.70%		1.70%
Subsequent Event [Member]
Debt Instrument [Line Items]
Unsecured Term Loan Repayment	$ 400
Credit Facility One [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity						$ 2,000
Uncommitted Credit Facilities With A Commercial Japanese Banks [Member]
Debt Instrument [Line Items]
Maximum amount of proceeds from sale of finance receivables			$ 196		¥ 22
De-recognized receivables			$ 157	$ 149
Average discounted rates of notes receivables			1.30%	1.60%	1.30%

Restructuring Related Activit39

Restructuring Related Activities (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		13 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Dec. 31, 2016
Restructuring and Related Cost [Line Items]
Restructuring Charges Incurred to Date					$ 33
Restructuring-related Costs Incurred to Date					49
Estimated costs of restructuring program by major type of cost
Payments for Restructuring			$ (33)		(60)
Restructuring Related Expenses	$ 15	$ 12	30	$ 22
Restructuring and Related Cost, Incurred Cost	16	26	35	39
Restructuring Charges	1	14	5	17
2014 Restructuring plan [Member]
Estimated costs of restructuring program by major type of cost
Restructuring and Related Cost, Incurred Cost		19		19
2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring Charges Incurred to Date					33
Restructuring-related Costs Incurred to Date					49
Estimated costs of restructuring program by major type of cost
Restructuring and Related Cost, Cost Incurred to Date	82		82		82
Payments for Restructuring			(33)		(60)
Substantially Completed Restructuring Programs [Member]
Estimated costs of restructuring program by major type of cost
Restructuring and Related Cost, Incurred Cost		7		20
Termination Benefits [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	0	0	0	0
Restructuring and Related Cost, Incurred Cost	0	14	3	15
Restructuring Charges	0	14	3	15
Termination Benefits [Member] | 2014 Restructuring plan [Member]
Estimated costs of restructuring program by major type of cost
Restructuring and Related Cost, Incurred Cost		18		18
Termination Benefits [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring Reserve	13		13		13	$ 16
Restructuring Charges Incurred to Date					27
Estimated costs of restructuring program by major type of cost
Payments for Restructuring			(6)		(14)
Restructuring Charges			3
Termination Benefits [Member] | Substantially Completed Restructuring Programs [Member]
Estimated costs of restructuring program by major type of cost
Restructuring and Related Cost, Incurred Cost		(4)		(3)
Accelerated depreciation [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	2	3	3	4
Restructuring and Related Cost, Incurred Cost	2	3	3	4
Restructuring Charges	0	0	0	0
Accelerated depreciation [Member] | 2014 Restructuring plan [Member]
Estimated costs of restructuring program by major type of cost
Restructuring and Related Cost, Incurred Cost		0		0
Accelerated depreciation [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring-related Costs Incurred to Date					5
Accelerated depreciation [Member] | Substantially Completed Restructuring Programs [Member]
Estimated costs of restructuring program by major type of cost
Restructuring and Related Cost, Incurred Cost		3		4
Transfer costs [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	12	7	24	12
Restructuring and Related Cost, Incurred Cost	12	7	24	12
Restructuring Charges	0	0	0	0
Transfer costs [Member] | 2014 Restructuring plan [Member]
Estimated costs of restructuring program by major type of cost
Restructuring and Related Cost, Incurred Cost		1		1
Transfer costs [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring-related Costs Incurred to Date					39
Estimated costs of restructuring program by major type of cost
Payments for Restructuring			(24)		(39)
Transfer costs [Member] | Substantially Completed Restructuring Programs [Member]
Estimated costs of restructuring program by major type of cost
Restructuring and Related Cost, Incurred Cost		6		11
Other [Member]
Restructuring and Related Cost [Line Items]
Restructuring Reserve	7		7		7	$ 6
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	1	2	3	6
Restructuring and Related Cost, Incurred Cost	2	2	5	8
Restructuring Charges	1	0	2	2
Other [Member] | 2014 Restructuring plan [Member]
Estimated costs of restructuring program by major type of cost
Restructuring and Related Cost, Incurred Cost		0		0
Other [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring Charges Incurred to Date					6
Restructuring-related Costs Incurred to Date					5
Estimated costs of restructuring program by major type of cost
Payments for Restructuring			(3)		(7)
Other [Member] | Substantially Completed Restructuring Programs [Member]
Estimated costs of restructuring program by major type of cost
Restructuring and Related Cost, Incurred Cost		2		8
Minimum [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring and Related Cost, Expected Cost	175		175		175
Estimated costs of restructuring program by major type of cost
Restructuring plan estimated future cash outflow			160
Minimum [Member] | Restructuring Plan [Member] | Termination Benefits [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring and Related Cost, Expected Cost	60		60		60
Minimum [Member] | Restructuring Plan [Member] | Other [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring and Related Cost, Expected Cost	10		10		10
Minimum [Member] | Restructuring Related To Plan [Member] | Other [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring and Related Cost, Expected Cost	105		105		105
Maximum [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring and Related Cost, Expected Cost	225		225		225
Estimated costs of restructuring program by major type of cost
Restructuring plan estimated future cash outflow			210
Maximum [Member] | Restructuring Plan [Member] | Termination Benefits [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring and Related Cost, Expected Cost	70		70		70
Maximum [Member] | Restructuring Plan [Member] | Other [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring and Related Cost, Expected Cost	20		20		20
Maximum [Member] | Restructuring Related To Plan [Member] | Other [Member] | 2016 Restructuring Plan [Member]
Restructuring and Related Cost [Line Items]
Restructuring and Related Cost, Expected Cost	135		135		$ 135
Cost of Sales [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	12	7	24	12
Cost of Sales [Member] | Termination Benefits [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	0	0	0	0
Cost of Sales [Member] | Accelerated depreciation [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	0	0	0	0
Cost of Sales [Member] | Transfer costs [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	12	7	24	12
Cost of Sales [Member] | Other [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	0	0	0	0
Selling, General and Administrative Expenses [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	3	5	6	10
Selling, General and Administrative Expenses [Member] | Termination Benefits [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	0	0	0	0
Selling, General and Administrative Expenses [Member] | Accelerated depreciation [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	2	3	3	4
Selling, General and Administrative Expenses [Member] | Transfer costs [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	0	0	0	0
Selling, General and Administrative Expenses [Member] | Other [Member]
Estimated costs of restructuring program by major type of cost
Restructuring Related Expenses	$ 1	$ 2	$ 3	$ 6

Supplemental Balance Sheet In40

Supplemental Balance Sheet Information (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Trade accounts receivable, net
Accounts receivable	$ 1,564		$ 1,564		$ 1,591
Less: allowance for doubtful accounts	(74)		(74)		(73)
Less: allowance for sales returns	(46)		(46)		(46)
Trade accounts receivable, net	1,444		1,444		1,472
Allowance for doubtful accounts
Beginning balance	75	$ 80	73	$ 75
Charges to expenses	2	3	5	7
Utilization of allowances	(3)	(3)	(4)	(2)
Ending balance	74	80	74	80
Inventories
Finished goods	652		652		625
Work-in-process	97		97		94
Raw materials	274		274		236
Inventories	1,023		1,023		955
Prepaid Expense and Other Assets, Current
Prepaid Expense	91		91		58
Restricted Cash and Cash Equivalents	251		251		243
Other Assets, Current	143		143		240
prepaid and other current assets	485		485		541
Property, plant and equipment, net
Land	92		92		91
Buildings and improvements	1,043		1,043		981
Equipment, furniture and fixtures	3,081		3,081		2,955
Capital in progress	305		305		338
Property, plant and equipment	4,521		4,521		4,365
Less: accumulated depreciation	2,870		2,870		2,735
Property, plant and equipment, net	1,651		1,651		1,630
Accrued expenses
Legal reserves	1,152		1,152		1,062
Payroll and related liabilities	486		486		572
Business Combination, Contingent Consideration, Liability, Current	39		39		63
Other	561		561		615
Accrued expenses	2,238		2,238		2,312
Other long-term liabilities
Accrued income taxes	797		797		781
Legal reserves	627		627		961
Business Combination, Contingent Consideration, Liability, Noncurrent	63		63		141
Other Accrued Liabilities, Noncurrent	485		485		455
Other long-term liabilities	1,972		1,972		$ 2,338
Accrued warranties
Beginning Balance			22	23
Provision			13	10
Settlements/ reversals			(13)	(13)
Ending Balance	22	20	22	20
Supplemental Balance Sheet Information
Depreciation expense	$ 65	$ 62	$ 127	$ 126

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2018	Jun. 30, 2018	Dec. 31, 2016
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Unrecognized Tax Benefits	$ 1,116		$ 1,116				$ 1,095
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	1,027		1,027				1,006
Incremental tax liability asserted by IRS	$ 1,162		$ 1,162
Reported tax rate	(60.30%)	47.80%	(10.10%)	97.00%
Net tax expense/benefits related to interest and penalties	$ 13	$ 13	$ 26	$ 23
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total	$ 612		$ 612				$ 572
Subsequent Event [Member]
Effective Income Tax Rate Reconciliation, Percent [Abstract]
Litigation Settlement, Amount					$ 275
Potential Reduction In Unrecognized Tax Benefits Over Next Twelve Months As Result Of Concluding Certain Matters						$ 757

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	3 Months Ended		6 Months Ended		9 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Mar. 31, 2018USD ($)	Jul. 26, 2017claims	Dec. 31, 2016USD ($)
Commitments and Contingencies (Textuals) [Abstract]
Accrual for legal matters that are probable and estimable | $	$ 1,779		$ 1,779				$ 2,023
Litigation Settlement, Expense | $	$ 205	$ 618	$ 208	$ 628
Subsequent Event [Member]
Loss Contingencies [Line Items]
Litigation Settlement, Amount | $					$ 275
Commitments and Contingencies (Textuals) [Abstract]
Product liability cases or claims related to mesh product						48,000
Putative class actions in the U.S., Mesh						8
Product liability cases or claims related to mesh product - Canada						20
Certified class actions in Canada, Mesh						1
Putative class actions in Canada, Mesh						3
Product liability cases or claims related to mesh product - United Kingdom						25
Assigned to one judge in MA [Member] | Subsequent Event [Member]
Commitments and Contingencies (Textuals) [Abstract]
Product liability cases or claims related to mesh product						3,100
Settled Litigation [Member] | Subsequent Event [Member]
Commitments and Contingencies (Textuals) [Abstract]
Product liability cases or claims related to mesh product						38,000
Total Product liability cases and claims settled related to Mesh product						14,500

Weighted Average Shares Outst43

Weighted Average Shares Outstanding (Details) - shares shares in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average shares outstanding - basic	1,369.8	1,357.4	1,367.6	1,353.9
Weighted Average Number Diluted Shares Outstanding Adjustment	21.3	0	23	0
Weighted average shares outstanding - assuming dilution	1,391.1	1,357.4	1,390.6	1,353.9
Stock Issued During Period, Shares, New Issues	1	4	8	12
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		17.7		18.6

Segment Reporting (Details)

Segment Reporting (Details) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)reportablesegments	Jun. 30, 2016USD ($)
Segment Reporting (Textuals) [Abstract]
Number of reportable segments | reportablesegments			3
Net sales
Net sales allocated to reportable segments	$ 2,281	$ 2,127	$ 4,485	$ 4,125
Impact Of Foreign Currency Fluctuations On Net Sales	(24)	(1)	(67)	(35)
Net sales	2,257	2,126	4,418	4,090
Operating Income Allocated to Reportable Segments	653	556	1,237	1,091
Amortization expense	(142)	(135)	(285)	(271)
Operating income (loss)	225	(334)	589	(41)
Other expense, net	(134)	(63)	(193)	(128)
Income (loss) before income taxes	91	(397)	396	(169)
Global Interventional Cardiology (IC) Reporting Unit [Member]
Net sales
Net sales allocated to reportable segments	612	580	1,217	1,140
Global Peripheral Interventions (PI) Reporting Unit [Member]
Net sales
Net sales allocated to reportable segments	277	260	545	508
Cardiovascular [Member]
Net sales
Net sales allocated to reportable segments	889	840	1,762	1,648
Operating Income Allocated to Reportable Segments	268	249	513	503
Global CRM Reporting Unit [Member]
Net sales
Net sales allocated to reportable segments	484	476	956	915
Global Electrophysiology (EP) Reporting Unit [Member]
Net sales
Net sales allocated to reportable segments	67	60	133	120
Rhythm Management [Member]
Net sales
Net sales allocated to reportable segments	551	536	1,089	1,035
Operating Income Allocated to Reportable Segments	115	73	216	140
Global Endoscopy (Endo) Reporting Unit [Member]
Net sales
Net sales allocated to reportable segments	405	361	792	700
Global Urology (Uro) Reporting Unit [Member]
Net sales
Net sales allocated to reportable segments	282	255	546	485
Global Neuromodulation (NM) Reporting Unit [Member]
Net sales
Net sales allocated to reportable segments	154	135	296	257
MedSurg [Member]
Net sales
Net sales allocated to reportable segments	841	751	1,634	1,442
Operating Income Allocated to Reportable Segments	270	234	508	448
Corporate expenses and currency exchange [Member]
Net sales
Operating (Loss) Income Unallocated to Segment	(66)	(58)	(153)	(99)
Special Charges [Member]
Net sales
Operating (Loss) Income Unallocated to Segment	$ (220)	$ (697)	$ (210)	$ (762)

Changes in Other Comprehensiv45

Changes in Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Changes in Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax	$ (58)	$ (59)	$ (58)	$ (59)	$ (71)	$ (79)	$ (38)	$ (54)
Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax	31	(1)	31	(1)	52	107	83	152
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	(4)		(4)		(6)	(6)
Accumulated Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Net of Tax	(22)	(10)	(22)	(10)	(21)	(21)	(10)	(10)
Accumulated Other Comprehensive Income (Loss), Net of Tax	(53)	(70)	(53)	(70)	$ (46)	$ 1	$ 35	$ 88
Cumulative Translation Adjustment, Net of Tax, Period Increase (Decrease)	13	(21)	21	(5)
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Before Reclassifications, Net of Tax	(4)	(64)	(41)	(102)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments, Net of Tax	0		0
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, before Reclassification Adjustments, Net of Tax	0	(1)	(2)	(3)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	9	(86)	(22)	(110)
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Reclassified from OCI, Net of Tax	(17)	(20)	(35)	(51)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	2	0	2	0
Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, Net of Tax	(1)	1	1	3
Other Comprehensive Income (Loss), Reclassifications out of OCI, Net of Tax	(16)	(19)	(32)	(48)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	13	(21)	21	(5)
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Net of Tax	(21)	(84)	(76)	(153)
Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, before Reclassification Adjustments and Tax	2		2
Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Adjustment, Net of Tax	1	0	1	0
Other Comprehensive Income (Loss), Net of Tax	(7)	(105)	(54)	(158)
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax	2	36	23	57
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising Reclassed from OCI, Tax	$ 10	$ 12	$ 20	$ 29

New Accounting Pronouncements N

New Accounting Pronouncements New ASU impacts (Details) $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)
New ASU impacts [Abstract]
Proceeds and Excess Tax Benefit from Share-based Compensation	$ 28
Cumulative Effect of New Accounting Principle in Period of Adoption	$ 76